

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/13, C07K 16/24, C12N 5/10, 15/85, A61K 39/395, 39/385		A2	(11) International Publication Number: WO 95/24481 (43) International Publication Date: 14 September 1995 (14.09.95)	
(21) International Application Number: PCT/US95/02400 (22) International Filing Date: 8 March 1995 (08.03.95) (30) Priority Data: 08/208,886 10 March 1994 (10.03.94) US (60) Parent Application or Grant (63) Related by Continuation US 08/208,886 (CIP) Filed on 10 March 1994 (10.03.94) (71) Applicant (for all designated States except US): SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): DALIE, Barbara [US/US]; 236 Park Avenue, Berkeley Heights, NJ 07922 (US). MILLER, Kenneth [US/US]; 11 Adams Avenue, Cranford, NJ 07016 (US). MURGOLO, Nicholas [US/US]; 99 Rolling Hill Drive, Millington, NJ 07946 (US). TINDALL, Stephen [US/US]; 40 Barnsdale Road, Madison, NJ 07940 (US).			(74) Agents: DULAK, Norman, C. et al.; Schering-Plough Corporation, Patent Dept. K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US). (81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG). Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(54) Title: HUMANIZED MONOCLONAL ANTIBODIES AGAINST HUMAN INTERLEUKIN-4 (57) Abstract <p>Humanized monoclonal antibodies are provided which are specific for human IL-4 and have properties unexpectedly superior to other, previously available humanized antibodies. Single-chain binding proteins, fusion proteins, and antigenic or IL-4 binding fragments of such antibodies are also provided by this invention. Also provided are nucleic acids which encode the heavy and light chain variable regions of such monoclonal antibodies or antigenic fragments thereof; anti-idiotypic antibodies; and methods for detecting, measuring and immunopurifying human IL-4, and for blocking or mimicking the biological activity of human IL-4.</p>				

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

HUMANIZED MONOCLONAL ANTIBODIES
AGAINST HUMAN INTERLEUKIN-4

5 This invention relates to polypeptides comprising variable regions of a humanized monoclonal antibody that specifically binds human IL-4, monoclonal antibodies and binding fragments comprising the polypeptides, and pharmaceutical compositions comprising the polypeptides,
10 antibodies and binding fragments. This invention also relates to nucleic acids and recombinant vectors encoding the foregoing, and to methods for making the polypeptides and antibodies.

BACKGROUND OF THE INVENTION

15 Human interleukin-4 (IL-4) is a highly pleiotropic lymphokine which affects many different components of the immune system. It has T cell growth factor (TCGF) activity and B cell growth factor activity. It is capable of potentiating the TCGF activity of interleukin-2 (IL-2) and the colony
20 forming activity of granulocyte-macrophage colony stimulating factor (GM-CSF). It also induces (a) the preferential production of IgG₁ and IgE, (b) the low affinity receptor for IgE (CD23), and (c) the expression of human leukocyte class II DR antigens.

 These activities suggest several possible therapeutic uses
25 for IL-4, e.g., as an anti-tumor agent [Tepper *et al.*, Cell 57:503 (1989)], a potentiating agent for IL-2 anticancer therapy, as a potentiating agent for GM-CSF-stimulated bone marrow regeneration, or as an agent to treat bare lymphocyte syndrome [Touraine, Lancet, pgs. 319-321 (February 7, 1981);
30 Touraine *et al.*, Human Immunology 2:147 (1981); and Sullivan *et al.*, J. Clin. Invest. 76:75 (1985)]. IL-4 and IL-4 agonists are thus potentially useful therapeutic agents.

- 2 -

On the other hand, the IgE- and CD23-inducing activity of IL-4 may have important adverse consequences for persons suffering from allergic diseases. The availability of IL-4 antagonists could provide an alternative to the use of glucocorticoid steroids, which have many deleterious side effects, especially with prolonged usage.

Monoclonal antibodies specific for blocking human IL-4 biological activity provide a means for constructing agonists or antagonists by generating anti-idiotypic antibodies (U.S. patent No. 4,731,237) or by mimotope screening [Geysen *et al.*, J. Immunol. Meth. 102:259 (1987); PCT patent applications WO 86/00991 and WO 86/06487]. Because most monoclonal antibodies are of rodent cell origin, however, there is a possibility that they would be immunogenic if used therapeutically in a human being, particularly over a long period of time.

To avoid this possibility, it is desirable to have human antibodies, or "humanized" antibodies, against human IL-4. The preparation of humanized antibodies against IL-4 has in fact been disclosed in International Patent Application Publication No. WO 93/17106. The disclosed antibodies while useful, however, do not have binding affinities equal to that of the starting rodent monoclonal antibody upon which they were based.

It would be desirable to have a humanized antibody against human IL-4 which would possess a binding affinity comparable to that of the rodent antibody. It cannot be predicted from the present state of the art, however, whether or how such an antibody could be produced.

SUMMARY OF THE INVENTION

The present invention provides such a high-affinity monoclonal antibody, methods and compositions useful for the

- 3 -

treatment of IL-4-related diseases, and intermediates for making such materials.

More particularly, this invention provides polypeptides comprising light or heavy chain variable regions of a humanized monoclonal antibody against human IL-4
5 which have amino acid sequences shown in SEQ ID NO: 70 and SEQ ID NO: 79, respectively, or subsequences of such sequences. In one embodiment, such polypeptides comprise a complete humanized monoclonal antibody. In other
10 embodiments they comprise IL-4-binding and/or antigenic fragments of the humanized monoclonal antibody.

The present invention further provides isolated DNAs that encode polypeptides comprising light or heavy chain variable regions of a humanized monoclonal antibody against
15 human IL-4 which have amino acid sequences shown in SEQ ID NO: 70 and SEQ ID NO: 79, respectively, or subsequences of such sequences.

The present invention also provides recombinant vectors and host cells comprising the foregoing DNAs, and methods for
20 making the polypeptides comprising culturing such host cells under conditions in which the DNAs are expressed.

This invention still further provides IL-4-binding compositions, single-chain binding proteins, fusion proteins and antibody fragments based on the humanized antibody.
25 Antibodies against the humanized antibody including anti-idiotypic antibodies, and fragments of such antibodies, are also provided by this invention, as are pharmaceutical compositions comprising a pharmaceutically acceptable carrier and one or more of the foregoing binding compositions,
30 proteins, polypeptides, antigenic fragments, antibodies or antibody fragments.

By administering an effective amount of one or more of the above-mentioned compositions, diseases or conditions mediated by human IL-4 can be treated.

- 4 -

BRIEF DESCRIPTION OF THE FIGURES

This invention can be more readily understood by reference to the accompanying Figures, in which:

Figure 1 shows amino acid residue replacements made in various humanized antibodies, compared to antibodies 25D2 and LAY.

Figure 2 is a graphical representation of the results of a competition assay in which the effects of varying concentrations of the indicated antibodies on the binding of a fixed amount of human ^{125}I -IL-4 to immobilized rat antibody 25D2 were measured. Bound radioactivity is shown as a function of free antibody concentration, both at 4°C and at room temperature.

Figure 3 is a graphical representation of the results of a bioassay in which the effects of varying concentrations of the indicated antibodies on the response of a Jijoye cell line to a fixed concentration of human IL-4 were measured by ELISA. Absorbance at 405 nM is shown as a function of antibody concentration.

DESCRIPTION OF THE INVENTION

All references cited herein are hereby incorporated in their entirety by reference.

Much of the work leading to precursor constructs used to make the present invention is described in International Patent Application Publication No. WO 93/17106. Reference should be made to this publication if it is desired to understand the strategy involved in making the humanized antibodies disclosed therein. All of the essential engineering steps required to make the starting constructs used in this invention, however, are detailed below.

As used herein, the terms "DNA" and "DNAs" are defined as molecules comprising deoxyribonucleotides linked in standard 5' to 3' phosphodiester linkage, including both

- 5 -

smaller oligodeoxyribonucleotides and larger deoxyribonucleic acids.

Antibodies comprise an assembly of polypeptide chains linked by disulfide bridges. Two principal polypeptide chains, referred to as the light chain and the heavy chain, make up all major structural classes (isotypes) of antibody. Both heavy chains and light chains are further divided into subregions referred to as variable regions and constant regions.

Heavy chains comprise a single variable region and three or four different constant regions, and light chains comprise a single variable region (different from that of the heavy chain) and a single constant region (different from those of the heavy chain). The variable regions of the heavy chain and light chain are responsible for the antibody's binding specificity.

As used herein, the term "heavy chain variable region" means a polypeptide (1) which typically is from 110 to 125 amino acids in length, and (2) whose amino acid sequence corresponds to that of a heavy chain of a monoclonal antibody of the invention, starting from the heavy chain's N-terminal amino acid. Likewise, the term "light chain variable region" means a polypeptide (1) which typically is from 95 to 115 amino acids in length, and (2) whose amino acid sequence corresponds to that of a light chain of a monoclonal antibody of the invention, starting from the light chain's N-terminal amino acid.

The terms Fab, Fc, F(ab)₂, and Fv are employed with their standard immunological meanings [Klein, *Immunology* (John Wiley, New York, 1982); Parham, Chapter 14, in Weir, ed. *Immunochemistry*, 4th Ed. (Blackwell Scientific Publishers, Oxford, 1986)].

As used herein the term "monoclonal antibody" refers to a homogeneous population of immunoglobulins which specifically bind to an epitope (i.e., antigenic determinant) of

- 6 -

human IL-4, the humanized antibody of this invention, or to antigenic fragments thereof.

Antigenic (i.e., immunogenic) fragments of the humanized antibody of this invention may or may not have IL-4-binding capability. Regardless of whether they bind IL-4, such fragments are useful as antigens for preparing antibodies by standard methods. These antibodies, whether polyclonal or monoclonal, can be used, e.g., in an immobilized form bound to a solid support by well known methods, to purify the humanized antibodies by immunoaffinity chromatography.

Antibodies against the antigenic fragments can also be used, unlabeled or labeled by standard methods, as the basis for immunoassays of the humanized antibodies. The particular label used will depend upon the type of immunoassay used. Examples of labels that can be used include but are not limited to radiolabels such as ^{32}P , ^{125}I , ^3H and ^{14}C ; fluorescent labels such as fluorescein and its derivatives, rhodamine and its derivatives, dansyl and umbelliferone; chemiluminescers such as luciferia and 2,3-dihydrophthal-azinediones; and enzymes such as horseradish peroxidase, alkaline phosphatase, lysozyme and glucose-6-phosphate dehydrogenase.

The antibodies can be tagged with such labels by known methods. For example, coupling agents such as aldehydes, carbodiimides, dimaleimide, imidates, succinimides, bisdiazotized benzadine and the like may be used to tag the antibodies with fluorescent, chemiluminescent or enzyme labels.

The general methods involved are well known in the art and are described, e.g., in *Immunoassay: A Practical Guide*, 1987, Chan (Ed.), Academic Press, Inc., Orlando, FL. Such immunoassays could be carried out, e.g., on fractions during purification of the humanized antibodies, or on serum samples

- 7 -

from patients receiving the humanized antibodies or fragments therefrom having IL-4-binding activity.

Of course, the humanized antibodies themselves or IL-4-binding fragments therefrom can also be used for the
5 immunoaffinity purification or immunoassay of human IL-4.

It is well known in the art that epitopes generally contain at least about five amino acid residues [Ohno *et al.*, Proc. Natl. Acad. Sci. USA 82:2945 (1985)]. Therefore, the antigenic fragments of this invention will typically comprise at
10 least five amino acid residues of the sequence of the complete heavy or light chain of the humanized antibody. Preferably, they will contain at least 7, and most preferably about 10 amino acid residues to ensure that they will be antigenic. Whether a given fragment is immunogenic can readily be
15 determined by routine experimentation.

Such antigenic fragments can be produced by proteolytic cleavage of the antibody or by chemical synthesis or recombinant technology and are thus not limited by proteolytic cleavage sites.

20 Preferably, smaller antigenic fragments will first be rendered more immunogenic by cross-linking or by coupling to an immunogenic carrier molecule (i.e., a macromolecule having the property of independently eliciting an immunological response in a host animal, to which the
25 polypeptides of the invention can be covalently linked). Cross-linking or conjugation to a carrier molecule may be required because small polypeptide fragments sometimes act as haptens (molecules which are capable of specifically binding to an antibody but incapable of eliciting antibody production,
30 i.e., they are not immunogenic). Conjugation of such fragments to an immunogenic carrier molecule renders them immunogenic through what is commonly known as the "carrier effect".

35

- 8 -

Suitable carrier molecules include, *e.g.*, proteins and natural or synthetic polymeric compounds such as polypeptides, polysaccharides, lipopolysaccharides etc. Protein carrier molecules are especially preferred, including but not
5 limited to keyhole limpet hemocyanin and mammalian serum proteins such as human or bovine gammaglobulin, human, bovine or rabbit serum albumin, or methylated or other derivatives of such proteins. Other protein carriers will be apparent to those skilled in the art. Preferably, but not
10 necessarily, the protein carrier will be foreign to the host animal in which antibodies against the fragments are to be elicited.

Covalent coupling to the carrier molecule can be achieved using methods well known in the art, the exact choice
15 of which will be dictated by the nature of the carrier molecule used. When the immunogenic carrier molecule is a protein, the fragments of the invention can be coupled, *e.g.*, using water soluble carbodiimides such as dicyclohexylcarbodiimide or glutaraldehyde.

20 Coupling agents such as these can also be used to cross-link the fragments to themselves without the use of a separate carrier molecule. Such cross-linking into aggregates can also increase immunogenicity. Immunogenicity can also be increased by the use of known adjuvants, alone or in
25 combination with coupling or aggregation.

Suitable adjuvants for the vaccination of animals include but are not limited to Adjuvant 65 (containing peanut oil, mannide monooleate and aluminum monostearate); Freund's complete or incomplete adjuvant; mineral gels such
30 as aluminum hydroxide, aluminum phosphate and alum; surfactants such as hexadecylamine, octadecylamine, lysolecithin, dimethyldioctadecyl-ammonium bromide, N,N-dioctadecyl-N',N'-bis(2-hydroxymethyl) propanediamine, methoxyhexadecylglycerol and pluronic polyols; polyanions
35 such as pyran, dextran sulfate, poly IC, polyacrylic acid and

- 9 -

carbopol; peptides such as muramyl dipeptide, dimethylglycine and tuftsin; and oil emulsions. The polypeptides could also be administered following incorporation into liposomes or other microcarriers.

5 Information concerning adjuvants and various aspects of immunoassays are disclosed, e.g., in the series by P. Tijssen, *Practice and Theory of Enzyme Immunoassays*, 3rd Edition, 1987, Elsevier, New York.

Serum produced from animals thus immunized can
10 be used directly. Alternatively, the IgG fraction can be separated from the serum using standard methods such as plasmaphoresis or adsorption chromatography using IgG specific adsorbents such as immobilized Protein A.

As used herein the term "binding composition" means a
15 composition comprising two polypeptide chains (1) which, when operationally associated, assume a conformation having high binding affinity for human IL-4, and (2) which are derived from a hybridoma producing monoclonal antibodies specific for human IL-4.

20 The term "operationally associated" is meant to indicate that the two polypeptide chains can be positioned relative to one another for binding by a variety of means, including association in a native antibody fragment, such as in an Fab or Fv fragment, or by way of genetically engineered
25 cysteine-containing or other linkers at the carboxyl termini.

Methods for making recombinant Fv fragments based on known antibody heavy and light chain variable region sequences are known in the art, having been described, e.g., by Moore *et al.* (U.S. Patent No. 4,642,334) and by Plückthun
30 [*Bio/Technology* 9:545 (1991)]. Alternatively, they can be chemically synthesized by standard methods.

Hybridomas of the invention used to make monoclonal antibodies against the humanized antibody of the invention or antigenic fragments thereof are produced by
35 well-known techniques. Usually, the process involves the

- 10 -

fusion of an immortalizing cell line with a B-lymphocyte that produces the desired antibody. Alternatively, non-fusion techniques for generating immortal antibody-producing cell lines are possible, and come within the purview of the present invention, e.g., virally-induced transformation [Casali *et al.*, Science 234:476 (1986)]. Immortalizing cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine, and human origin. Most frequently, rat or mouse myeloma cell lines are employed as a matter of convenience and availability.

Techniques for obtaining the appropriate lymphocytes from mammals injected with the target antigen are well known. Generally, peripheral blood lymphocytes (PBLs) are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. A host animal is injected with repeated dosages of the purified antigen, and the animal is permitted to generate the desired antibody-producing cells before these are harvested for fusion with the immortalizing cell line. Techniques for fusion are also well known in the art, and in general involve mixing the cells with a fusing agent, such as polyethylene glycol.

Hybridomas are selected by standard procedures, such as HAT (hypoxanthine-aminopterin-thymidine) selection. From among these hybridomas, those secreting the desired antibody are selected by assaying their culture medium by standard immunoassays, such as Western blotting, ELISA (enzyme-linked immunosorbent assay), RIA (radioimmunoassay), or the like. Antibodies are recovered from the medium using standard protein purification techniques [Tijssen, *Practice and Theory of Enzyme Immunoassays* (Elsevier, Amsterdam, 1985)]. Many references are available for guidance in applying any of the above techniques [Kohler *et al.*, *Hybridoma Techniques* (Cold Spring Harbor Laboratory, New York, 1980); Tijssen, *Practice*

- 11 -

and *Theory of Enzyme Immunoassays* (Elsevier, Amsterdam, 1985); Campbell, *Monoclonal Antibody Technology* (Elsevier, Amsterdam, 1984); Hurrell, *Monoclonal Hybridoma Antibodies: Techniques and Applications* (CRC Press, Boca Raton, FL, 1982)]. Monoclonal antibodies can also be produced using well known phage library systems.

The use and generation of antibody fragments is also well known, e.g., Fab fragments [Tijssen, *Practice and Theory of Enzyme Immunoassays* (Elsevier, Amsterdam, 1985)], Fv fragments [Hochman *et al.*, *Biochemistry* 12:1130 (1973); Sharon *et al.*, *Biochemistry* 15:1591 (1976); Ehrlich *et al.*, U.S. Patent No. 4,355,023] and antibody half molecules (Auditore-Hargreaves, U.S. Patent No. 4,470,925).

Hybridomas and monoclonal antibodies of the invention are produced using either glycosylated or unglycosylated versions of the recombinantly-produced humanized antibodies. Generally, unglycosylated versions are produced in *E. coli*, and glycosylated versions are produced in yeast or mammalian cell hosts, e.g., Chinese hamster ovary (CHO), COS monkey or mouse L cells.

The recombinantly-produced humanized antibodies are produced by introducing an expression vector into a host cell using standard protocols [Maniatis *et al.*, *Molecular Cloning: A Laboratory Manual* (Cold Spring Harbor Laboratory, New York, 1982); Okayama and Berg, *Mol. Cell. Biol.* 2:161 (1982); Okayama and Berg, *Mol. Cell. Biol.* 3:280 (1983); Hamer, *Genetic Engineering* 2:83 (1980); U.S. Patent No. 4,599,308; Kaufman *et al.*, *Mol. Cell. Biol.* 2:1304 (1982)].

Construction of bacterial or mammalian expression vectors is well known in the art, once the nucleotide sequence encoding a desired protein is known or otherwise available. For example, DeBoer (U.S. Patent No. 4,511,433) has disclosed promoters for use in bacterial expression vectors. Goeddel *et al.* (U.S. Patent No. 4,601,980) and Riggs (U.S. Patent No. 4,431,739) have disclosed the production of mammalian

- 12 -

proteins by *E. coli* expression systems. Riggs (*supra*), Ferretti *et al.* [Proc. Natl. Acad. Sci. 83:599 (1986)], Sproat *et al.* [Nucleic Acids Res. 13:2959 (1985)] and Mullenbach *et al.* [J. Biol. Chem. 261:719 (1986)] disclose how to construct synthetic genes for expression in bacteria.

5 The present invention is based upon the surprising discovery that a humanized antibody against human IL-4 disclosed in International Patent Application Publication No. WO 93/17106 could be further engineered using methods
10 not disclosed in the publication to produce a new humanized antibody having markedly superior properties. This new antibody, designated h25D2-9, is characterized in part by activities in an IL-4 competition binding assay and in a bioassay that are comparable to those of rodent monoclonal
15 antibody 25D2, upon which the humanized antibody is based.

Although the best humanized antibody disclosed in International Patent Application Publication No. WO 93/17106, designated h25D2-1, produced similar results in the competition binding assay at 4°C, antibody h25D2-9 appeared
20 to be considerably more potent than antibody h25D2-1 at room temperature. The improved activity shown by antibody h25D2-9 at the higher temperature makes that antibody more suitable for therapeutic use.

New humanized antibody h25D2-9 is further
25 characterized by a surprisingly increased expression in COS cells, compared to the previously disclosed humanized antibodies. Available data suggest that this increased expression, which is five to ten times greater than the expression of antibody h25D2-1 in the same cells, may be
30 due to enhanced chain association within the cells. The present invention, however, is in no way dependent upon whether this possible explanation is correct or not.

Humanized antibody h25D2-9 was designed by introducing further framework modifications into antibody
35 h25D2-1. This procedure, which involved replacement of

- 13 -

some non-consensus framework residues with either rodent or consensus human residues, was carried out by following to some extent the rules disclosed by Adair *et al.* in International Patent Application Publication No. WO 91/09967.

5 As noted in the Examples below, however, the methods of Adair *et al.* were followed with modification. Furthermore, there is evidence to show that if the procedures of Adair *et al.* were applied *de novo* to rodent monoclonal antibody 25D2, a humanized antibody having the superior characteristics of
10 antibody h25D2-9 could not have been produced. What is required is modification of starting construct h25D2-1 following the rules of Adair *et al.* as modified herein.

 The nucleotide sequences of cDNAs encoding the heavy (VH) and light (VL) chain variable regions of anti-human IL-4
15 monoclonal antibody 25D2, the production of which is described below, are defined in the Sequence Listing by SEQ ID NOs:1 and 2, respectively. The amino acid sequences predicted from these nucleotide sequences are also defined in SEQ ID NOs: 1 and 2.

20 The nucleotide and predicted amino acid sequences of the variable regions of the light and heavy chains of antibody h25D2-9 are shown in SEQ ID NOs: 70 and 79, respectively, although those skilled in the art will appreciate that these sequences also contain subsequences that are not
25 in the variable region.

 In particular, the variable region sequences contain secretory leader sequences that typically are cleaved during post-translational processing in eukaryotic cells to produce the mature forms. The putative amino-terminal residues for
30 the mature forms of the light and heavy chains are indicated in SEQ ID NOs: 70 and 79. Although the indicated leader sequences were used, those skilled in the art will recognize that many other well known leaders, including non-antibody leaders, could have been used instead.

- 14 -

The variable regions shown in SEQ ID NOs: 70 and 79 can also form the basis for the design of non-peptide mimetic compounds that mimic the functional properties of antibody h25D2-9. Methods for producing such mimetic compounds have been described, e.g., by Saragovi *et al.* [Science 253:792 (1991)].

In addition to providing a basis for making a superior humanized antibody against human IL-4, the information in SEQ ID NOs:70 and 79 can be used to produce single-chain IL-4 binding proteins comprising linked heavy and light chain fragments of the Fv region, as described by Bird *et al.* [Science 242:423 (1988)], or biosynthetic antibody binding sites (BABS), as described by Huston *et al.* [Proc. Natl. Acad. Sci. USA 85:5879 (1988)]. Single-domain antibodies comprising isolated heavy-chain variable domains [Ward *et al.*, Nature 341:544 (1989)] can also be prepared using the disclosed sequence information.

The present invention can also be used to construct bi-specific antibodies which have binding specificity for another antigen, as well as for IL-4. Such antibodies can be constructed by known methods, e.g., by chemical reassociation of half molecules as described by Brennan *et al.* [Science 229:81 (1985)].

The variable regions of antibody h25D2-9 can also be coupled together in a polypeptide, either directly or by a linker sequence. One or more of the variable regions can also be engineered into another (non-immunoglobulin) polypeptide or protein, thereby conferring IL-4 binding capability on the polypeptide or protein.

The light and heavy chains of antibody h25D2-9 can also be used in conjunction with the complementary chain from another monoclonal antibody, resulting in a kind of "hybrid" antibody. For example, the heavy chain of antibody h25D2-9 has been combined with the light chain of antibody h25D2-1, and vice versa. If the complementary

- 15 -

chain selected is from a rodent antibody specific for human IL-4, such as antibody 25D2, a "semi-humanized" antibody would result. Whether such antibodies have adequate affinity for IL-4 can readily be determined by routine

5 experimentation, using the methods described herein.

Polypeptides "comprising light or heavy chain variable regions of a humanized monoclonal antibody against human IL-4 which have amino acid sequences shown in SEQ ID NO: 70 and SEQ ID NO: 79, respectively, or subsequences of such
10 sequences," are defined herein to include all of the foregoing derivative forms of the specific binding region of antibody h25D2-9. Of course, it is the mature forms absent any secretory leader that would be used.

Nucleic acids encoding the heavy and light chain
15 variable regions of antibody h25D2-9 can be prepared by standard methods using the nucleic acid sequence information provided in SEQ ID NOs: 70 and 79. For example, DNA can be chemically synthesized using, e.g., the phosphoramidite solid support method of Matteucci *et al.*
20 [J. Am. Chem. Soc. 103:3185 (1981)], the method of Yoo *et al.* [J. Biol. Chem. 264:17078 (1989)], or other well known methods. This can be done by sequentially linking a series of oligonucleotide cassettes comprising pairs of synthetic oligonucleotides, as described below.

25 Of course, due to the degeneracy of the genetic code, many different nucleotide sequences can encode polypeptides having the amino acid sequences defined by SEQ ID NOs: 70 and 79 or subsequences thereof. The codons can be selected for optimal expression in prokaryotic or eukaryotic systems.
30 Such degenerate variants are also encompassed by this invention.

Insertion of the DNAs encoding the heavy and light chain variable regions of antibody h25D2-9 into a vector is easily accomplished when the termini of both the DNAs and
35 the vector comprise compatible restriction sites. If this cannot

- 16 -

be done, it may be necessary to modify the termini of the DNAs and/or vector by digesting back single-stranded DNA overhangs generated by restriction endonuclease cleavage to produce blunt ends, or to achieve the same result by filling in the single-stranded termini with an appropriate DNA polymerase.

Alternatively, any site desired may be produced, e.g., by ligating nucleotide sequences (linkers) onto the termini. Such linkers may comprise specific oligonucleotide sequences that define desired restriction sites. Restriction sites can also be generated by the use of the polymerase chain reaction (PCR). See, e.g., Saiki *et al.*, Science 239:487 (1988). The cleaved vector and the DNA fragments may also be modified if required by homopolymeric tailing.

Expression of the nucleic acids encoding the polypeptide chains of the humanized antibodies of this invention can be carried out by conventional methods, using either one or two expression vectors. Synthesis of the complete antibodies can be carried out in a single host cell, or the heavy and light chains can be made in two different host cells, and then combined. The methodology involved is disclosed, e.g., in U.S. Patent No. 4,816,397 to Boss *et al.* and in U.S. Patent No. 4,816,567 to Cabilly *et al.*

The polypeptides, antibodies and fragments of this invention can be purified by standard methods, including but not limited to preparative disc-gel electrophoresis, isoelectric focusing, HPLC, reversed-phase HPLC, gel filtration, ion exchange and partition chromatography, ligand affinity chromatography with Proteins A or G, and countercurrent distribution. Purification methods for antibodies are disclosed, e.g., in *The Art of Antibody Purification*, 1989, Amicon Division, W.R. Grace & Co.

Pharmaceutical compositions can be prepared using the monoclonal antibodies, binding compositions, fusion proteins or single-chain binding proteins of the invention, or

- 17 -

anti-idiotypic antibodies prepared against such monoclonal antibodies, to treat IL-4-related diseases.

Some of the compositions have IL-4 blocking or antagonistic effects and can be used to suppress IL-4 activity.

- 5 Such compositions comprise, e.g., the monoclonal antibodies, binding compositions or single-chain binding proteins of the invention and a physiologically acceptable carrier.

- 10 Other compositions comprise anti-idiotypic antibodies prepared using the monoclonal antibodies of the invention as an antigen and a physiologically acceptable carrier. These anti-idiotypic antibodies, which can be either monoclonal or polyclonal and are made by standard methods, may mimic the binding activity of IL-4 itself. If they do, they may potentially be useful as IL-4 agonists.

- 15 The humanized antibodies (or binding fragments) of this invention may be used in the form of complexes in which the antibodies are bound to IL-4. Such complexes may extend the serum half-life of IL-4, and thus produce sustained release, by decreasing the rate of clearance. They may also produce
20 controlled release of the IL-4, as the IL-4 slowly dissociates from the complexes.

- The dosage regimen involved in a therapeutic application will be determined by the attending physician, considering various factors which may modify the action of the antibodies,
25 e.g., the condition, body weight, sex and diet of the patient, the severity of any infection, time of administration, and other clinical factors.

- Typical protocols for the therapeutic administration of antibodies are well known in the art and have been disclosed,
30 e.g., by Elliott *et al.* [*The Lancet* 344:1125 (1994)], Isaacs *et al.* [*The Lancet* 340:748 (1992)], Anasetti *et al.* [*Transplantation* 54:844 (1992)], Anasetti *et al.* [*Blood* 84:1320 (1994)], Hale *et al.* [*The Lancet* 2:1394 (December 17, 1988)], Queen [*Scrip* 1881:18 (1993)] and Mathieson *et al.* [*N. Eng. J. Med.* 323:250
35 (1990)].

- 18 -

Administration of the compositions of this invention is typically parenteral, by intraperitoneal, intravenous, subcutaneous, or intramuscular injection, or by infusion or by any other acceptable systemic method. Administration by
5 intravenous infusion, typically over a time course of about 1 to 5 hours, is preferred.

Often, treatment dosages are titrated upward from a low level to optimize safety and efficacy. Generally, daily antibody dosages will fall within a range of about 0.01 to 20 mg protein
10 per kilogram of body weight. Typically, the dosage range will be from about 0.1 to 5 mg protein per kilogram of body weight.

Where IL-4 is complexed by specific binding to the antibodies or binding fragments of the invention, the
15 amounts of the complexes used should typically be adjusted to contain from about 0.001 to about 50 μ g of IL-4 per kg body weight per day. Preferably, the amount of complexed IL-4 administered will range from about 0.01 to about 10 μ g per kg per day; most preferably from about 0.05 to about 2 μ g per kg
20 per day.

Although the compositions of this invention could be administered in simple solution, they are more typically used in combination with other materials such as pharmaceutical carriers. Useful pharmaceutical carriers can be any
25 compatible, non-toxic substance suitable for delivering the compositions of the invention to a patient. Sterile water, alcohol, fats, waxes, and inert solids may be included in a carrier. Pharmaceutically acceptable adjuvants (buffering agents, dispersing agents) may also be incorporated into the
30 pharmaceutical composition. Generally, compositions useful for parenteral administration of such drugs are well known; e.g. *Remington's Pharmaceutical Science*, 17th Ed. (Mack Publishing Company, Easton, PA, 1990). Alternatively, compositions of the invention may be introduced into a

- 19 -

patient's body by implantable drug delivery systems [Urquhart *et al.*, Ann. Rev. Pharmacol. Toxicol. 24:199 (1984)].

Therapeutic formulations may be administered in any conventional dosage formulation. Formulations typically
5 comprise at least one active ingredient, together with one or more acceptable carriers. Formulations may include those suitable for oral, rectal, nasal, or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration.

10 The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. See, e.g., Gilman *et al.* (eds.) (1990), *The Pharmacological Bases of Therapeutics*, 8th Ed., Pergamon Press; and Remington's *Pharmaceutical Sciences*,
15 *supra*, Easton, Penn.; Avis *et al.* (eds.) (1993) *Pharmaceutical Dosage Forms: Parenteral Medications* Dekker, New York; Lieberman *et al.* (eds.) (1990) *Pharmaceutical Dosage Forms: Tablets* Dekker, New York; and Lieberman *et al.* (eds.) (1990),
20 *Pharmaceutical Dosage Forms: Disperse Systems* Dekker, New York.

EXAMPLES

The following non-limiting Examples will serve to illustrate the present invention. Selection of vectors and hosts as well as the concentration of reagents, temperatures, and the
25 values of other variables are only to exemplify application of the present invention and are not to be considered limitations thereof.

Unless otherwise indicated, percentages given below for solids in solid mixtures, liquids in liquids, and solids in liquids
30 are on a wt/wt, vol/vol and wt/vol basis, respectively. Sterile conditions were maintained during cell culture.

Example I. Cloning of Antibody 25D2General Methods and Reagents

Unless otherwise noted, standard recombinant DNA methods were carried out essentially as described by Maniatis
5 *et al.*, *Molecular Cloning: A Laboratory Manual*, 1982, Cold Spring Harbor Laboratory.

Small scale isolation of plasmid DNA from saturated overnight cultures was carried out according to the procedure of Birnboim *et al.* [Nuc. Acids Res. 7:1513 (1979)]. This
10 procedure allows the isolation of a small quantity of DNA from a bacterial culture for analytical purposes. Unless otherwise indicated, larger quantities of plasmid DNA were prepared as described by Clewell *et al.* [J. Bacteriol. 110:1135 (1972)].

Specific restriction enzyme fragments derived by the
15 cleavage of plasmid DNA were isolated by preparative electrophoresis in agarose. Gels measuring 9 x 5 1/2 cm were run at 50 mA for 1 hour in Tris-Borate buffer (Maniatis *et al.*, *supra*, p. 454) and then stained with 0.5 µg/ml ethidium bromide to visualize the DNA. Appropriate gel sections were
20 excised, and the DNA was electroeluted (Maniatis *et al.*, *supra*, p. 164). After electroelution, the DNA was phenol extracted (Maniatis *et al.*, *supra*, p. 458) and ethanol precipitated (Maniatis *et al.*, *supra*, p. 461).

Restriction enzymes and T4 DNA ligase were purchased
25 from New England Biolabs (Beverly, MA). Superscript RNase H⁻ reverse transcriptase was from BRL/Gibco (Rockville, MD), Taq DNA polymerase from Stratagene (LaJolla, CA), DNA polymerase Klenow fragment from Pharmacia LKB Biotechnology, Inc. (Piscataway, NJ), calf intestinal phosphatase
30 from Boehringer Mannheim Biochemicals (Indianapolis, IN) and RNasin from Promega (Madison, WI). All enzymes were used in accordance with the manufacturers' instructions. The

- 21 -

Sequenase version 2.0 sequencing system was obtained from United States Biochemical (Cleveland, OH).

Deoxynucleotide triphosphates and oligo dT₁₂₋₁₈ primer were from Pharmacia LKB Biotechnology, bovine serum
5 albumin from Boehringer Mannheim Biochemicals and re-distilled phenol from BRL/Gibco.

The plasmid vector Bluescript was purchased from Stratagene, while competent *E. coli* strain DH5-alpha (Max Efficiency) was from BRL/Gibco.

10 Tissue culture media and supplements were from BRL/Gibco, and fetal calf serum was from Hyclone Laboratories, Inc. (Logan, UT).

Cell Culture

Hybridoma cell line MP4.25D2.11 was maintained in
15 RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum, 2 mM glutamine and 10 units/ml penicillin/streptomycin in a humidified 37°C chamber with 5% CO₂.

Isolation and Sequencing of Monoclonal Antibody 25D2

20 Medium conditioned by hybridoma cell line MP4.25D2.11 was concentrated 10-40 fold by ultrafiltration and then applied to a GAMMABIND G[®]-Agarose column in 0.01 M sodium phosphate, pH 7.0, 0.15 M NaCl, with 0.005% sodium azide. GammaBind G-Agarose is a beaded agarose to which
25 recombinant streptococcal Protein G has been covalently immobilized. The bound protein was then eluted with 0.5 M acetic acid adjusted to pH 3.0 with ammonium hydroxide. Fractions containing purified monoclonal antibody 25D2 were
30 identified by sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE), essentially as described by Laemmli [Nature 227:680 (1970)].

- 22 -

Two methods were used to separate the heavy and light chains of purified antibody 25D2 for sequence determination. The first method employed semi-preparative SDS-PAGE followed by electroblotting onto a polyvinylidene difluoride (PVDF) membrane. Briefly, 120 μ g (800 pmoles) of the highly purified antibody were subjected to slab gel electrophoresis in SDS after reduction with 2-mercapto-ethanol (Laemmli, *supra*). The resolved heavy and light chains were then transferred onto an IMMOBILON® membrane (a PVDF membrane from Millipore, Bedford, MA), essentially using the electroblotting method of Matsudaira [J. Biol. Chem. 261:10035 (1987)]. The bands corresponding to the heavy and light chains were excised from the membrane following staining with Coomassie Brilliant Blue and processed for N-terminal sequencing.

The other method permitted larger amounts of the heavy and light chains to be isolated in solution. Using this method, a 6 ml sample of purified antibody 25D2 containing 1 mg/ml protein was dialyzed against 0.1 M Tris-HCl, 1 mM EDTA, pH 8.0, at 4°C and then subjected to oxidative sulfitolysis in NaSO₃/Na₂S₂O₆, essentially as described by Morehead *et al.* [Biochemistry 23:2500 (1984)].

Following sulfitolysis, the antibody preparation was dialyzed against 1 M acetic acid, lyophilized to dryness, reconstituted in 1 M acetic acid to a volume of 1.5 ml, and subjected to gel filtration in a 1 x 30 cm SEPHADEX G-75® column (Pharmacia, Piscataway, NJ) equilibrated with the same buffer.

Fractions enriched in heavy and light chains were pooled separately and separately subjected to gel filtration in a 1.5 x 100 cm SEPHADEX G-75® column in 1 M acetic acid. The purity of the heavy and light chains following this step was assessed by analytical SDS-PAGE. Fractions containing the heavy (4 nmoles) and light (3 nmoles) chains were pooled separately and concentrated *in vacuo* to about 0.1 ml-volumes for sequencing.

- 23 -

All N-terminal amino acid sequencing was performed using an Applied Biosystems Model 477A protein-peptide sequencer. Sequencing of the isolated heavy and light chains blotted onto the IMMOBILON® membrane was carried out
5 essentially as described by Yuen *et al.* [Biotechniques 7:74 (1989)]. Analysis of the isolated chains in solution was performed following the instructions of the manufacturer of the sequencer.

Oligonucleotide Primer Design and Cloning Strategy

10 Based upon information obtained from the foregoing amino acid sequence analyses, degenerate oligonucleotide primers were designed for use in PCR. One degenerate primer designated B1798 had a nucleotide sequence encoding the amino-terminal 13 amino acid residues of the mature heavy
15 chain of 25D2. Another degenerate primer designated B1873 had a nucleotide sequence encoding the amino-terminal 7 amino acid residues of the mature light chain of the antibody.

A non-degenerate oligonucleotide primer designated B1797 having a nucleotide sequence corresponding to a
20 segment in the 3' untranslated region of DNA encoding the antibody heavy chain [Bruggemann *et al.*, Proc. Natl. Acad. Sci. USA 83:6075 (1986)] was also designed, as was a non-degenerate oligonucleotide primer designated B1868 having a nucleotide sequence corresponding to a segment in
25 the kappa constant region of DNA encoding the antibody light chain [Sheppard *et al.*, Proc. Natl. Acad. Sci. USA 78:7064 (1981)].

Other non-degenerate primers were designed for use in isolation of cDNA encoding the variable regions of the heavy
30 and light chains of antibody 25D2, based upon nucleotide sequence information obtained following PCR amplification of cDNA encoding the complete heavy and light chains.

- 24 -

Oligonucleotide Synthesis

Oligonucleotide primers having sequences defined in the Sequence Listing were synthesized by standard methods using an Applied Biosystems Model 380B Synthesizer.

5 The designations of these primers, followed in parentheses by the corresponding sequence identification numbers, are as follows:

	B1797 (SEQ ID NO: 5)
	B1798 (SEQ ID NO: 6)
10	B1868 (SEQ ID NO: 7)
	B1873 (SEQ ID NO: 8)
	B1884 (SEQ ID NO: 9)
	B1902 (SEQ ID NO: 10)
	B1921 (SEQ ID NO: 11)
15	B1922 (SEQ ID NO: 12)
	B1932 (SEQ ID NO: 13)
	T3 (SEQ ID NO: 14)
	T7 (SEQ ID NO: 15)

20 Primers B1798 and B1873 were designed to define a 5' *NorI* restriction site to facilitate cloning. Primers B1797 and B1868 were designed to define a 3' *SpeI* restriction site, for the same reason.

RNA Isolation

25 Total cytoplasmic RNA was isolated from hybridoma cell line MP4.25D2.11 by incubating the cells for 15 minutes in a lysis buffer consisting of 10 mM Tris-HCl, pH 7.4, 10 mM NaCl, 2 mM MgCl₂ and 0.5% Nonidet P40 (an octylphenol-ethylene oxide condensate containing an average of 9 moles ethylene oxide per mole of phenol). After a centrifugation step at
30 2,000 x g for 5 minutes at 4°C, the nuclear pellet was

- 25 -

discarded and the supernatant fluid was re-centrifuged at 10,000 x g for 15 minutes at 4°C.

After the second centrifugation step, the supernatant fluid was mixed with an equal volume of a solution containing
5 200 mM NaCl, 10 mM Tris-HCl, pH 7.4, 20 mM ethylenediaminetetraacetate (EDTA) and 2% sodium dodecylsulfate (SDS). The mixture was extracted once with an equal volume of Tris-buffered phenol/chloroform (1:1) and once with chloroform. Following the extractions, the mixture
10 was precipitated overnight with 1/20 volume of 0.2 M sodium acetate, pH 5.5, and 2.5 volumes of absolute ethanol at -20°C.

First Strand Synthesis

First strand cDNA was synthesized directly from total cytoplasmic RNA at 37°C for 90 minutes in a 10 µl reaction
15 volume. The reaction mixture contained 5.6 µl of RNA in diethylpyrocarbonate-treated distilled H₂O, 0.25 µl of RNasin (40,000 units/ml), 2 µl of 5X reverse transcriptase reaction buffer (250 mM Tris-HCl, pH 8.3, 200 mM KCl, 30 mM MgCl₂, 3 mM dithiothreitol), 0.25 µl of bovine serum albumin (4
20 mg/ml), 1 µl of 10 mM dNTP mixture (dATP, TTP, dCTP, dGTP), 0.4 µl of oligo dT primer (0.5 mg/ml) and 0.5 µl of Superscript RNase H⁻ reverse transcriptase (200 units/ml).

Polymerase Chain Reaction

PCR amplifications were carried out using a Techne
25 programmable thermal cycler. The PCR reaction mixtures consisted of 10 µl of first strand cDNA reaction mixture, 53.5 µl of distilled H₂O, 10 µl of 10X Taq polymerase reaction buffer (500 mM KCL, 100 mM Tris-HCl, pH 8.3, 15 mM MgCl₂, 0.1% gelatin), 16 µl of 1.25 mM dNTP mixture (dATP, TTP,
30 dCTP, dGTP), 5 µl of each primer of interest (20 pmol/µl) and 0.5 µl of *Thermus aquaticus* DNA polymerase.

- 26 -

The PCR conditions included 30 cycles of: denaturation at 95°C for 2 minutes, primer annealing at 37°C for 2 minutes, primer extension at 72°C for 3 minutes and a final extension period of 9 minutes at 72°C. At the end of amplification, 1 µl of 100 mM dNTP mixture and 1 µl of DNA polymerase Klenow fragment (5 units/µl) were added to each of the PCR reactions, and the fill-in step was allowed to proceed for 10 minutes at room temperature.

The PCR mixtures were subjected to electrophoresis in 1% agarose/Tris-borate gels containing 0.5 µg/ml ethidium bromide. The PCR fragments of interest were excised from the gels and purified by electroelution.

Subcloning and DNA Sequencing

The gel-purified PCR fragments were digested with *NotI* and *SpeI* and then ligated to dephosphorylated *NotI/SpeI*-digested Bluescript plasmid vector at 15°C for 16-24 hours in a mixture containing 50 mM Tris-HCl, pH 7.5, 10 mM MgCl₂, 10 mM dithiothreitol, 50 µg/ml bovine serum albumin, 1 mM ATP and 10 units of T4 DNA ligase. Competent *E. coli* strain DH5-alpha (Max Efficiency) cells were transformed with the ligation mixture.

Diagnostic analysis of the resulting transformants was carried out by restriction digests with *NotI* and *SpeI*, as well as by PCR with the oligonucleotide primers used in the initial PCR reactions. The inserts of the subclones of interest were subjected to DNA sequencing using the Sequenase system.

Oligonucleotide primers T7, B1884, B1921 and B1922 were used to obtain DNA encoding the variable region of the heavy chain. Primers T3, B1902 and B1932 were used to obtain DNA encoding the variable region of the light chain.

- 27 -

CDR Determinations

The CDRs within the variable regions of the heavy and light chains of monoclonal antibody 25D2 were determined both by the method of Kabat *et al.*, [*Sequences of Proteins of Immunological Interest*, 4th Edition, 1987, U.S. Department of Health and Human Services, National Institutes of Health], and by computer binding site loop analysis. For the latter analysis, a Silicon Graphics Personal Iris Model 4D/25 computer was employed using Sybyl or IMPACT software. The approach taken involved essentially a combination of the three-dimensional modeling methods of Seville *et al.* [Biochemistry 27:8344 (1988)], the immunoglobulin hypervariable region conformation analytical methods of Chothia *et al.* [J. Mol. Biol. 196:901 (1987); Nature 342:877 (1989)] and the protein loop conformation analytical methods of Tramontano *et al.* [PROTEINS: Structure, Function and Genetics 6:382 (1989)].

Example II Antibody Humanization

General Methods and Reagents

Restriction enzymes and DNA modifying enzymes were from New England Biolabs. Taq polymerase was obtained from Perkin-Elmer Cetus, Inc. Mouse anti-human IgG4-Fc antibody was purchased from CalBiochem. Sheep anti-human IgG (H+L) peroxidase conjugate and human IgG4 protein standards were obtained from The Binding Site, Inc. Goat anti-rat IgG was purchased from Jackson Immuno-Research Labs.

Purified human IL4 (hIL4) was obtained from a bacterial expression system essentially as described by Lundell *et al.* [J. Indust. Microbiol. 5:215 (1990)] and radioiodinated by the IODOGEN® (Pierce Chemical Co.) method, according to the manufacturers instructions. A purified rat monoclonal antibody, designated 25D2, has been described by DeKruyff *et al.* [J. Exp. Med. 170:1477 (1989)].

- 28 -

Human growth hormone (hGH) standards and a goat anti-rabbit IgG peroxidase conjugate were purchased from Boehringer-Mannheim Biochemicals, Inc. Rabbit anti-hGH was from Dako Corp., and sheep anti-hGH was obtained from Biodesign International. Protein-G SEPHAROSE® CL-4B was purchased from Pharmacia, Inc. Oligonucleotides were synthesized using an Applied Biosystems (ABI) 380B DNA synthesizer.

10 Bacterial Strains, Plasmids, Cell Lines
and Recombinant DNA Methods

All plasmids were propagated in *E. coli* K-12 strain MM294 (ATCC 33625). Bluescript (KS) and Bluescribe plasmids were obtained from Stratagene Inc. Plasmids pDSRS (ATCC 68232) and pSRS (ATCC 68234) are available from the American Type Culture Collection (ATCC). Plasmid HuCK encoding the human kappa constant region and plasmid p24BRH encoding the human IgG4 constant region were obtained from the ATCC (under Accession Nos. ATCC 59173 and ATCC 57413, respectively). Plasmid vectors pUC19 and pSV.Sport were from BRL/GIBCO (Gaithersburg, MD).

COS 7 cells obtained from the ATCC (ATCC CRL 1651) were propagated in Dulbecco's Modified Eagle's Medium (DMEM)/high glucose supplemented with 10% FBS and 6 mM glutamine. CHO cell line DXB11 was obtained from Dr. L. Chasin (Columbia University, NY,NY) and was propagated before transfection in Ham's F12 medium supplemented with 10% FBS, 16 mM glutamine, 0.1 mM nonessential amino acids, 0.1 mM hypoxanthine and 0.016 mM thymidine. Transfected CHO cells were propagated in DMEM/high glucose supplemented with 10% dialyzed FBS, 18 mM glutamine, and 0.1 mM nonessential amino acids for selection.

- 29 -

A Jijoye cell line stably transformed by a recombinant vector comprising a human growth hormone reporter gene operably linked to a human germline ϵ transcript promoter (called C12 cells) and a Jijoye cell line expressing large quantities of the human IL-4 receptor on the cell surface (called CJ cells) were obtained from Dr. Chung-Her Jenh at Schering-Plough Corporation. Both cell lines were propagated in RPMI (Gibco) containing 15% horse serum, 5% FBS, 6 mM glutamine, 0.1 mM nonessential amino acids, 0.5 mg/ml geneticin (Gibco). Unless otherwise stated, recombinant DNA methods were performed as described by Maniatis *et al.*, *supra*.

PCR was performed under standard conditions [Saiki *et al.*, Science 230:1350 (1985)], and the sequences of fragments generated by PCR were confirmed by either manual or automated DNA sequencing. Manual DNA sequencing was performed with SEQUENASE® (United States Biochemical Co.) according to the manufacturer's instructions. Automated DNA sequencing was performed on an ABI 373A DNA sequencer using the Taq polymerase cycle sequencing kit provided by ABI, according to the manufacturer's recommendations. Plasmid DNA was prepared for transfections using Qiagen columns (Qiagen, Inc.), according to the manufacturer's instructions.

25 Determination of Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA)

Antibody concentrations were determined by an IgG4-specific ELISA. Briefly, Nunc MAXISORB® Immunoplates were coated at 4°C for at least 4 hours with a mouse anti-human IgG4-Fc monoclonal antibody at 5 μ g/ml in 50 mM bicarbonate buffer, pH 9.5. The plates were blocked for 1 hour at room temperature in Blocking buffer [3% bovine serum albumin (BSA) in Dulbecco's modified phosphate buffered saline (PBS; Gibco-BRL)]. After washing the plates with Wash

- 30 -

buffer (10 mM potassium phosphate, pH 7.4, 0.05% Tween-20), serially diluted samples, either as purified antibodies or conditioned medium, in a volume of 100 μ l were applied to the wells of the plates.

- 5 Conditioned medium containing the humanized antibodies was typically concentrated 10-30-fold by centrifugation filtration (Amicon, Inc) prior to assay. The plates were incubated for 1-2 hours at room temperature, after which the samples were aspirated and the wells were
10 washed 3 times. One hundred microliters of anti-human IgG (H+L) peroxidase conjugate were added to each well and the plates were incubated for 1 hour at room temperature. The plates were then washed 3 times and 100 μ l of ABTS
15 peroxidase substrate (Boehringer-Mannheim Biochemicals) was added to each well for detection of the immune complexes. The plates were read spectrophotometrically at 405 nm.

Transfections

- For each of the recombinant antibodies described below,
20 5 μ g of both the heavy and light chain plasmids were transfected into 5×10^6 COS 7 cells in a total volume of 250 μ l by electroporation using a Biorad Gene Pulser. After 4 hours, the medium (DMEM plus 10% FBS) was replaced with DMEM minus serum. The cells were propagated for 72 hours, after
25 which the medium was harvested, clarified by centrifugation, and stored at -20°C for subsequent antibody purification. To obtain larger quantities of the humanized antibodies, recombinant CHO cell lines were established that produced antibodies designated h25D2-1 or h25D2-4.
30 To isolate stable CHO cell lines, 20 μ g of the appropriate heavy and light chain plasmid DNAs [molar ratio of heavy chain plasmid:light chain plasmid (with the *dhfr* gene) 10:1] were transfected into 5×10^6 CHO DXB11 cells by the calcium

- 31 -

phosphate precipitation method [Graham *et al.*, Virology 52:456 (1973)]. After two days, the cells were selected for resistance to hypoxanthine and thymidine starvation, i.e. *dhfr* expression [Schimke *et al.*, Methods in Enzymology 151:85 (1987)].

Clones secreting antibody were identified by ELISA, expanded and subjected to methotrexate-mediated gene amplification. Clones secreting the greatest amount of antibody were expanded into roller bottles, and the serum-free medium was harvested continuously. Confluent roller bottle cultures were propagated in serum-containing medium for 48 hours, after which the cells were rinsed with Dulbecco's Modified PBS and the medium was replaced with a serum-free preparation. The serum-free medium was harvested after 3-4 days for subsequent antibody purification.

Antibody Purification

Serum-free conditioned medium containing the antibodies was passed over a Mab TRAP® column of streptococcal protein G-SEPHAROSE® CL-4B (Pharmacia), and the antibodies were eluted according to the manufacturer's instructions. Final antibody concentrations were determined by ELISA as described above.

Affinity Measurements

A. Affinity Constants

To determine whether the humanized antibodies were capable of binding human IL-4, apparent dissociation constants were determined by coating immunoplates with mouse anti-human IgG4-Fc (capture antibody) and blocking the plates as described above for the ELISA assay. After washing the wells, the plates were incubated at room temperature for 2 hours with concentrated conditioned

- 32 -

medium containing one of the humanized antibodies (100 μ l/well). Wild-type rat antibody 25D2 was assayed in parallel for comparison, using an anti-rat IgG as the capture antibody.

5 The wells were washed and incubated with 125 I-hIL-4 at concentrations between 4,000 and 2 pM in final volumes of 100 μ l. All assays were performed in triplicate, and the background binding was determined by using a 1000-fold molar excess of unlabelled hIL4 in control wells. After incubation for 2 hours at room temperature, the wells were
10 washed, the protein was solubilized in 75 μ l of Solubilization buffer [0.1 N NaOH/1% sodium dodecylsulfate (SDS)], and the solution was counted in an LKB gamma counter. Concentrations of bound and free hIL4 were determined, and the affinities of the antibodies were determined by Scatchard
15 plot analysis [Berzofsky *et al.*, in *Fundamental Immunology*, 1984, Paul, E.E., Ed., Raven Press, New York, New York, pp. 595-644].

B. Competitive Binding Analysis

A comparison of antigen binding by wild-type rat
20 antibody 25D2 and the humanized antibodies was made using a plate binding competition assay in which the binding of labelled human IL-4 (125 I-hIL-4) to plates coated with antibody 25D2 was measured in the presence of unlabelled antibody 25D2, humanized antibody h25D2-1 or humanized
25 antibody h25D2-4, all of which had been purified.

Immunosorb plates were coated with a 60 ng/ml solution of the rat 25D2 antibody diluted in PBS (100 μ l/well) for at least 16 hours at 4°C. The wells were then blocked with Blocking buffer (3% BSA in PBS) for 4 hours at room
30 temperature. Fifty microliters of 2-fold serially diluted competing antibodies plus the appropriate amount of 125 I-hIL-4 (60 μ l total volume) were added to each well, and the plates were incubated at room temperature for 16-24

- 33 -

hours. The plates were washed 3 times with potassium phosphate, pH 7.4, plus 0.05% Tween 20. The wells were aspirated dry, and 75 μ l of Solubilization buffer (0.1 N NaOH/1% SDS) was added to each well and incubated for 5 30 minutes at room temperature. The solution was removed from each well and counted in an LKB gamma counter.

Inhibition of Receptor Binding

The humanized antibodies were assayed for the ability to inhibit the binding of radiolabelled hIL-4 to the 10 recombinant human IL-4 receptor expressed on Jijoye CJ cells in microtiter plates. Briefly, the humanized antibodies were serially diluted in cell growth medium at protein concentrations of from 8.6 nM to 4 pM. Rat antibody 25D2 was similarly diluted and used as a positive control. Jijoye 15 CJ cells (10^5 cells) and 44 pM 125 I-hIL-4 were then added to each well (200 μ l final volume per well) and the plates were incubated for 2 hours at 4°C.

After the incubation, the contents of the wells were mixed and 185 μ l were removed and layered onto sucrose 20 cushions (150 μ l of 5% sucrose in growth medium plus 0.02% sodium azide). After centrifugation (1500 rpm, 4°C, 10 minutes), the tubes were quick-frozen in liquid nitrogen, and the bottoms of the tubes containing the cell pellets were clipped and counted in a gamma counter. Bound cpm was 25 plotted vs. the antibody concentration, and the humanized antibodies were compared to the native antibody at the concentrations required to cause 50% inhibition of receptor binding (IC_{50}).

30 Germline Epsilon Promoter Reporter Gene Assay

Jijoye C12 cells were seeded into 96 well dishes at a density of 4×10^5 cells/125 μ l/well in medium. Serially diluted test antibodies and 1 ng/mL hIL-4 were added to

- 34 -

the cells, and the plates were incubated at 37°C for about 64 hours. After the incubation, 100 µl of the conditioned medium were removed from each well and added to individual wells of an immunoplate previously coated with a 1:2000 dilution of sheep anti-human growth hormone (αhGH) in sodium carbonate buffer, pH 9.5. The plates were incubated at room temperature for 2 hours and washed 5 times with 10 mM potassium phosphate buffer containing 0.05% Tween-20. One hundred microliters of a rabbit anti-human growth hormone antiserum (diluted 1:1000) were added to each well, and incubation was continued for 1 hour.

The wells were washed again as described above, and 100 µl of a horse-radish peroxidase conjugated goat anti-rabbit IgG (diluted 1:10,000) was added to each well. After washing, 100 µl of ABTS peroxidase substrate was added to the wells for detection of the immune complexes. The plates were read spectrophotometrically at 405 nm.

Optical density (O.D.) at 405 nm was plotted vs. antibody concentration, and the humanized antibodies were compared to the native antibody at the concentrations required to cause 50% inhibition of the expression of the human growth hormone under the control of the germline ε promoter (IC₅₀).

Humanized Antibodies

Homology Modeling

Using the methods described above, it was determined that antibody LAY was an optimal human framework candidate. LAY heavy and light chain pairs were first pursued.

A listing of potential minimal and maximal 25D2 residues that could be grafted into the framework sequences were determined by the above-described methods to be as shown in Table 1.

- 35 -

Table 1

	<u>Residues^a</u>
5 VH Minimal List:	28,30,31,32,53,54,56,100, 101,103,105,106,107
VH Maximal List ^b :	33,35,50,51,52,57,58 59,61,65,109,110
VL Minimal List:	29,30,31,50,52,91,94
VL Maximal List ^b :	24,34,46,49,53,54,56

10

^a Residues for VH and VL refer to the residue numbers in
SEQ ID NO: 1 and SEQ ID NO: 2, respectively.

^b The VH and VL Maximal Lists include the corresponding
15 Minimal Lists and the further indicated residues.

Specific constructs described below contain the following
residues from the foregoing Table:

- 36 -

Table 2

	<u>Humanized Antibody</u>	<u>Residues</u>
5	h25D2H-1, L	VH LAY Maximal; VL LAY Maximal
	h25D2H-1, L-1	VH LAY Maximal; VL LAY Maximal (less residues 46 and 49)
10	h25D2H-2, L-1	VH LAY Maximal; VL LAY Maximal (less residues 33 and 35) (less residues 46 and 49)
	h25D2H-3, L-1	VH LAY Maximal; VL LAY Maximal (less residues 28 and 30) (less residues 46 and 49)
15	h25D2H-4, L-1	VH LAY Maximal; VL LAY Maximal (less Residues 28, 30 and 65) (less residues 46 and 49)
20	h25D2H-5,L-1	VH LAY Maximal; VL LAY Maximal (less residues 33, 35 and 65) (less residues 46 and 49)

Construction of Humanized 25D2
Light Chain Expression Vectors

25 The nucleotide sequence of DNA for an initial version
of the humanized 25D2 light chain (h25D2L), including
(from 5' to 3') fifteen 5' noncoding bases and bases encoding
an initiating methionine residue, a leader sequence and the
variable region of the antibody, together with the
corresponding amino acid sequence of the leader and the
30 antibody, is defined in the Sequence Listing by SEQ ID NO: 16.

- 37 -

In the construction of this humanized light chain, silent restriction endonuclease cleavage sites were deduced from the Genetics Computer Group (GCG; Madison, WI) SILENT MAP® program. Nucleotide sequences selected to encode the protein sequence utilized codons found in the rat 25D2 sequence, although several codons were changed to create restriction endonuclease cleavage sites.

The entire variable region of the antibody was cloned as three contiguous DNA fragments that were synthesized as pairs of oligonucleotides. These pairs of oligonucleotides were amplified by PCR and joined at unique restriction endonuclease cleavage sites. The result was three fragments (numbered from 5' to 3') delineated by *EcoRI/KpnI* (fragment 1), *KpnI/PstI* (fragment 2) and *PstI/MscI* (fragment 3) sites. In the amplification reactions, the two oligonucleotides in each pair were complementary to each other over a stretch of 18-24 nucleotides. Therefore each oligonucleotide served as a template for the other.

The designations of these oligonucleotide primers, followed in parentheses by the corresponding sequence identification numbers, were as follows:

2481 (SEQ ID NO: 17)
2482 (SEQ ID NO: 18)
2700 (SEQ ID NO: 19)
2641 (SEQ ID NO: 20)
2483 (SEQ ID NO: 21)
2491 (SEQ ID NO: 22)
2662 (SEQ ID NO: 23)
2661 (SEQ ID NO: 24)

The synthesis of fragment 1 required two PCR amplifications. An initial PCR using primers 2481 and 2482 generated a fragment lacking a translational initiation sequence and the leader peptide coding sequence. This

- 38 -

fragment was reamplified with primers 2700 and 2641 to add on an *EcoRI* site followed by the translational initiation and leader peptide coding sequences. The final fragment 1 thus contained at its 5' terminus an *EcoRI* site followed by a
5 translational initiation sequence [Kozak, Nucleic Acids Res. 12:857 (1984)] and a sequence encoding a leader peptide corresponding to the anti-CAMPATH-1 antibodies [Reichmann *et al.*, Nature 332:323 (1988)].

The fragment 1 sequence extended through a *KpnI* site
10 and encoded amino acid residues 1-36 of the variable region of the humanized light chain. Fragment 2 encoded residues 36-79 of the humanized light chain, including a *KpnI* and *PstI* site at the 5' and 3' termini, respectively. Fragments 1 and 2 were joined at the unique *KpnI* site and subcloned into the
15 Bluescript (KS) vector between the *EcoRI* and *PstI* sites in the vector to create fragment 1-2. Fragment 3 encoded the remaining amino acids of the variable domain (residues 78-106) and extended from the *PstI* site through an *MscI* site (located 22 bases upstream of the 3' terminus of the variable
20 domain), and included an *EcoRI* site at the 3' end.

Fragment 3 was subcloned into a Bluescript (KS) vector between the *PstI* and *EcoRI* sites in the vector. A 321 bp fragment (fragment 4) containing 22 nucleotides at the 3' end of the humanized variable region, including the *MscI* site,
25 joined to the coding sequence for the entire human kappa constant region, was generated by PCR using the HuCK plasmid as template and primers 2856 and 2857, the sequences of which are defined by SEQ ID NO: 25 and SEQ ID NO: 26, respectively. In addition to the *MscI* site at the 5' end of
30 fragment 4, an *EcoRI* site was included on the 3' end to facilitate cloning.

Fragment 4 was joined to fragment 3 between the common *MscI* site within the variable region and the *EcoRI* site present on the 3' end of fragment 4 and the vector. An
35 *EcoRV* site was present downstream of fragment 3-4 in the

- 39 -

vector. Fragment 3-4 was removed as a *Pst*I/*Eco*RV fragment and was ligated to fragment 1-2 between the common *Pst*I site in the variable region and the blunt-ended *Sma*I site in the vector. The entire coding region for the h25D2L light chain could be obtained after cleavage at the *Sal*I and *Bam*HI sites flanking the coding region in the Bluescript vector.

The mammalian expression vector was constructed by first cleaving the Bluescript vector containing the h25D2L sequence at the 3' end with *Bam*HI, and then treating the cleavage product with Klenow fragment DNA polymerase, under conditions that left flush ends. Next, the h25D2L DNA fragment was obtained after cleavage at the 5' end with *Sal*I. Finally, the h25D2L coding region was ligated to vector pDSRS which had previously been digested with *Sal*I and *Sma*I. The completed vector, designated pSDh25L, contained the entire coding region for the humanized 25D2 antibody including the signal peptide and the human kappa constant region.

Co-transfection of the foregoing h25D2L DNA with a heavy chain DNA (designated h25D2H-1; prepared as described below) into COS 7 cells did not produce measurable antibody expression, although antibody expression was observed when the h25D2L DNA was co-transfected with DNA for a humanized heavy chain from an unrelated antibody (data not shown).

Since the h25D2L light chain was capable of being expressed with an unrelated heavy chain, it was possible that the sequence of either the humanized 25D2 light chain or the humanized heavy chain was inhibiting h25D2 antibody expression.

Examination of the Fv interface of the 25D2 molecular model suggested that replacement of the human LAY residues leucine 46 and tyrosine 49 with animal residues phenylalanine 46 and phenylalanine 49 could affect the ability of h25D2L to combine with the heavy chain. In addition, comparison of human kappa chain variable region sequences in the

- 40 -

- Swiss-Prot protein database (Bairoch, Amos) and the human kappa light chain subgroup I according to Kabat *et al.*, *Sequences of Proteins of Immunological Interest, supra*, revealed that the leucine at amino acid position 46 and the tyrosine at amino acid position 49 were highly conserved. Therefore, the foregoing humanized light chain gene was reconstructed to introduce mutations at these positions. In addition, an arginine residue at position 107 that had been omitted in the h25D2L DNA was replaced.
- 10 To modify the h25D2L DNA, two pairs of oligonucleotide primers were synthesized to perform PCR-based mutagenesis of the h25D2L coding region. Primer 3016 (SEQ ID NO: 28), which was used as the 5' primer, encompassed the coding region for amino acid residues 38-51 of the light chain
- 15 variable domain and included a *StuI* site at the 5' end. Primer 3016 also incorporated three nucleotide changes into the h25D2L sequence. This resulted in replacement of a phenylalanine residue with a leucine residue (F46L) at position 46 of the amino acid sequence, and replacement of a
- 20 phenylalanine residue at position 49 with a tyrosine codon (F49Y) at position 49. A 3' primer designated 3017 (SEQ ID NO: 29) encompassed the *PstI* site at position 237.
- A 126 bp fragment was generated by PCR using oligonucleotide primers 3016 and 3017 and the h25D2L Bluescript plasmid as template DNA. The *StuI/PstI* PCR
- 25 fragment was used to replace the corresponding fragment in vector h25D2L, thereby incorporating the F46L, F49Y changes.
- An oligonucleotide primer designated 3018 (used as a 5' primer; SEQ ID NO: 30) was synthesized which encompassed
- 30 amino acid residues 95-106 of the light chain variable region, including the *MscI* site at the 5' terminus, and the first three residues of the human kappa constant region. In addition, a codon for arginine (R107) was inserted at the junction of the variable and constant regions in the primer. Another primer
- 35 designated 3019 (SEQ ID NO: 31) was synthesized to serve as a

- 41 -

3' primer. This primer corresponded to sequences in the Bluescript vector including the *Bam*HI and *Spe*I sites.

Using primers 3018 and 3019 and the h25D2L Bluescript plasmid as template, a fragment was generated by PCR that
5 included residues 95-107 of the variable domain and the entire coding region of the human kappa chain. This *Msc*I/*Spe*I PCR fragment was used to replace the corresponding fragment in the F46L, F49Y vector described above. After confirming the DNA sequence of the PCR
10 fragments, the vector was digested with *Spe*I and treated with Klenow fragment DNA polymerase under conditions that generated flush-ended termini. A fragment containing the entire coding region of humanized antibody light chain h25D2L-1 was isolated after *Sal*I digestion and ligated to the
15 pDSRS vector previously digested with *Sal*I and *Sma*I. The resulting h25D2L-1 expression vector containing the F46L, F49Y, and R107 mutations of h25D2L was designated pKM20.

The nucleotide sequence of the DNA for the modified version of the humanized 25D2 light chain, including (from
20 5' to 3') fifteen 5' noncoding bases and bases encoding an initiating methionine residue, a leader sequence and the variable region of the antibody, together with the corresponding amino acid sequence of the leader and the antibody, is defined in the Sequence Listing by SEQ ID NO: 27.

25 Construction of Humanized 25D2 Heavy Chain Expression Vectors

The nucleotide sequence of DNA for an initial version of the humanized 25D2 heavy chain (h25D2H-1), including
30 (from 5' to 3') fifteen 5' noncoding bases and bases encoding an initiating methionine residue, a leader sequence and the variable region of the antibody, together with the corresponding amino acid sequence of the leader and the antibody, is defined in the Sequence Listing by SEQ ID NO: 32.

- 42 -

The nucleotide sequences that were selected to encode the protein sequence, including the signal peptide, utilized codons found in the rat 25D2 sequence. Several codons were changed to create restriction endonuclease cleavage sites.

5 The entire variable region was cloned as three contiguous DNA fragments that were synthesized as pairs of oligonucleotides. These pairs of oligonucleotides were amplified by the PCR and joined at unique restriction endonuclease cleavage sites. The result was three fragments
10 (numbered from 5' to 3') delineated by *Sall/SmaI* (fragment 1), *SmaI/PstI* (fragment 2) and *PstI/ApaI* (fragment 3) sites. In the amplification reactions, the two oligonucleotides in each pair were complementary to each other over a stretch of
15 template for the other.

The designations of these oligonucleotide primers and the corresponding SEQ ID NOs defining their sequences were as follows:

	<u>Oligonucleotide</u>	<u>SEQ ID NO.</u>
20	2588	33
	2589	34
	2232	35
	2445	36
	2446	37
25	2447	38
	2523	39
	2580	40
	2642	41
	2646	42

30 The synthesis of fragment 1 required two amplification reactions. An initial PCR product of primers 2588 and 2599 was subjected to a second round of amplification with oligonucleotides 2232 and 2445, to yield fragment 1. The final fragment 1 thus contained at its 5' terminus a *SaII* site

- 43 -

followed by a translational initiation sequence (Kozak, *supra*) and a sequence encoding the leader peptide corresponding to the anti-CAMPATH-1 antibodies (Reichmann *et al.*, *supra*). The fragment 1 sequence extended through a *Sma*I site and
5 included the coding sequence for amino acid residues 1-42 of the variable region of the humanized heavy chain.

Fragment 2 encoded residues 42-82 of the humanized heavy chain, including a *Sma*I site and a *Pst*I site at the 5' and 3' ends, respectively. Fragments 1 and 2 were joined at the
10 unique *Sma*I site and subcloned into the Bluescript (KS) vector between the *Sal*I and *Pst*I sites in the vector, to create plasmid pBS1-2.

Fragment 3 encoded the remaining amino acids of the variable domain (residues 81-121) and extended from the
15 *Pst*I site through the 3' terminus of the variable region and on through thirty nucleotides of the coding sequence for the human IgG4 constant region. A unique *Apa*I site was located within sixteen nucleotides of the IgG4 constant sequence in fragment 3. The synthesis of fragment 3 also required two
20 amplification reactions. An initial PCR product of primers 2523 and 2580 was subjected to a second round of amplification with primers 2642 and 2646, to yield fragment 3.

To prepare an initial heavy chain expression vector,
25 plasmid p24BRH was cleaved with *Apa*I and *Sac*I, and an *Apa*I/*Sac*I fragment containing IgG4 genomic DNA was isolated. Fragment 3 was ligated to a common *Apa*I site on the isolated fragment from plasmid p24BRH. A resulting *Pst*I/*Sac*I fragment (encompassing residues 81-121 of the h25D2H-1
30 variable region joined to IgG4 DNA encoding the complete IgG4 constant region) was then ligated to a Bluescribe plasmid that had previously been cleaved with *Pst*I and *Sac*I, to produce a plasmid designated pAS6.

- 44 -

The IgG4 genomic DNA was then replaced with the cDNA. First, a plasmid containing the IgG4 cDNA inserted between the *Pst*I and *Not*I sites of the pSV.Sport vector was cleaved at the *Pst*I site in the vector upstream of the cDNA and at a
 5 *Bst*EII site within the IgG4 cDNA. This plasmid had been constructed as follows.

Oligonucleotide primers corresponding to the entire heavy chain variable region (VH) of an unrelated humanized antibody were synthesized by standard methods. The
 10 designations of these oligonucleotides and the corresponding SEQ ID NOs defining their sequences were as follows:

	<u>Oligonucleotide</u>	<u>SEQ ID NO.</u>
	B2474CC	43
	B2419CC	44
15	B2420CC	45
	B2475CC	46
	B2477CC	47
	B2479CC	48

Pairs of oligonucleotides B2474CC and B2419CC, B2420CC
 20 and B2475CC, B2477CC and B2479CC were heat-denatured, annealed, and incubated with Taq polymerase or Pfu (Stratagene, La Jolla, CA). In the polymerase chain reactions (PCRs), the two oligonucleotides in each pair were complementary to each other by about 24 to 30 nucleotides.
 25 Therefore, each oligonucleotide served as the template for the other.

The PCRs were carried out for 18 cycles, after which the three resulting DNA fragments, corresponding to the three consecutive segments of VH, designated VH1, VH2 and VH3,
 30 were electrophoresed in an agarose gel and purified by electroelution.

- 45 -

The relative order of the three V_H DNA fragments, restriction sites for cloning, and the multicloning-site map of cloning vector used, pSV.Sport, were as follows:

	<u>Fragment</u>	<u>Restriction Sites</u>	<u>PCR Primers</u>
5	VH1	<i>EcoRI</i> _____ <i>SpeI</i>	B2474CC + B2419CC
	VH2	<i>SpeI</i> _____ <i>XbaI</i>	B2420CC + B2475CC
	VH3	<i>EcoRI/XbaI</i> _____ <i>SalI/ApaI/SstI</i>	B2477CC + B2479CC

Multi-cloning Sites of pSV.Sport

PstI/KpnI/RsrII/EcoRI/SmaI/SalI/SstI/SpeI/NorI/XbaI/BamHI/HindIII/SnaBI/MluI

- 10 Fragment VH1 was restricted with enzymes *EcoRI* and *SpeI* and cloned into vector pSV.Sport. Fragment VH2 was subsequently joined to VH1 in pSV.Sport by directional insertion at *SpeI* and *XbaI* sites. Fragment VH3 was separately cloned into pSV.Sport as an *EcoRI/XbaI-SalI/ApaI/SstI*
- 15 fragment. The three fragments were verified by DNA sequencing.

- Full-length V_H cDNA of the unrelated antibody was assembled by first joining VH3 to a genomic DNA of the γ 4 H-chain constant region (CH) and then attaching the VH3-CH
- 20 fragment to the VH1-VH2 fragment, as is described more fully below.

- To facilitate synthesis and secretion of the heavy chain, a coding sequence for a leader peptide was inserted into the DNA. The amino acid and nucleotide sequences of this leader
- 25 are those of the leader of the anti-CAMPATH-1 antibodies (Reichmann *et al.*, *supra*).

- To construct DNA encoding a full-length antibody H-chain, the V_H synthetic cDNA was combined with human γ 4 constant-region genomic DNA (ATCC 57413) using *ApaI*
- 30 restriction cleavage and ligation. This procedure was initiated by digesting plasmid pSV.Sport containing VH3 with *NorI* followed by treatment with Klenow DNA polymerase

- 46 -

(Boehringer Mannheim) to generate blunt ends. The resulting DNA was ethanol-precipitated, resuspended, and digested with *ApaI*. This restricted plasmid DNA was ligated with the *ApaI/SmaI* restriction fragment of the genomic $\gamma 4$ constant region.

The VH3-CH genomic DNA was then excised as an *XbaI/HindIII* fragment and inserted into pSV.Sport already containing VH1-VH2, thereby completing assembling of the full-length heavy chain DNA.

In subsequent manipulations, a human $\gamma 4$ constant-region cDNA was designed and constructed to replace the genomic DNA. This was accomplished using six oligonucleotide PCR primers that were synthesized by standard methods. The designations of these oligonucleotides and the corresponding SEQ ID NOs defining their sequences were as follows:

	<u>Oligonucleotide</u>	<u>SEQ ID NO.</u>
	B2491CC	4 9
	B2498CC	5 0
20	B2499CC	5 1
	B2597CC	5 2
	B2598CC	5 3
	B2656CC	5 4

Primers B2491CC, B2499CC and B2598CC corresponded to the plus strand of $\gamma 4$ constant region cDNA. Primers B2498CC, B2597CC and B2656CC corresponded to the minus strand. Using human $\gamma 4$ genomic DNA as the template, three consecutive double-stranded DNA fragments encompassing the entire $\gamma 4$ constant-region coding cDNA were generated by PCR.

- 47 -

The three CH DNA segments, restriction sites for cloning, and primers used were as follows:

	<u>Segment</u>	<u>Restriction Sites</u>	<u>PCR Primers</u>
	CH A.	<i>Sall</i> _____ <i>EcoRI</i>	B2491CC + B2498CC
5	CH B.	<i>EcoRI</i> _____ <i>XhoI/Sall</i>	B2499CC + B2500CC
	CH C.	<i>Sall/XhoI</i> _____ <i>NotI</i>	B2598CC + B2656CC

Segment A was cloned into pUC19 as a *Sall/EcoRI* restriction fragment. Segment C, as a *Sall/XhoI-NotI* restriction fragment, was cloned into pSV.Sport. Segment B, as an *EcoRI-XhoI/Sall* fragment, was cloned into pSV.Sport already containing segment C. All three segments were verified by DNA sequencing.

The $\gamma 4$ cDNA was assembled by excising segment A with *PstI* and *EcoRI*, and cloning this fragment into pSV.Sport already containing segments B and C. The restriction map of the human $\gamma 4$ CH cDNA and its relative position in pSV.Sport multi-cloning sites are as follows:

A B C

20 *PstI/Sall*-----*EcoRI*-----*XhoI*-----*NotI/HindIII/SnaBI/MluI*

The $\gamma 4$ CH cDNA was excised as a *Sall---HindIII* fragment to replace the genomic $\gamma 4$ fragment in the previously described full-length H-chain construct. The final product was the pSVSPORT-1 vector that was cleaved as described above.

25 Next, plasmid pAS6 was linearized with *PstI* and partially digested with *BstEII* within the IgG4 sequence. A fragment containing a segment of the coding sequences of the variable region from the *PstI* site (amino acid residues 81-121) and the IgG4 cDNA to the *BstEII* site (residues 122-191) was isolated and subcloned into the pSV.Sport containing the IgG4 cDNA, between the *PstI* and *BstEII* sites. 30 The construct, designated pAS7, encompassed residues 81-121

- 48 -

of the variable region joined to the entire IgG4 cDNA flanked by a 5' *Pst*I site and a 3' *Xba*I site.

Plasmid pAS7 was cleaved with *Pst*I and *Xba*I, and the fragment (containing residues 81-121 of the variable region and the IgG4 constant region cDNA) was subcloned into vector pBS1-2 (containing fragment 1-2) between the *Pst*I and *Xba*I sites. This vector, designated pDA5, was then linearized with *Sac*I and treated with T4 DNA polymerase under conditions that left flush ends. The entire coding region of the h25D2H-1 heavy chain was isolated after *Sal*I digestion and ligated to vector pSRS, which had previously been cleaved with *Sal*I and *Sma*I. The final plasmid was designated pSh25D2H-1.

Four variants of the h25D2H-1 heavy chain (designated h25D2-2 through h25D2-5) were constructed. The amino acid changes incorporated into the four variants are indicated in Fig. 1, in which amino acid residues are shown using standard single-letter abbreviations, and the sequences within CDRs 1, 2 and 3 of antibody 25D2 and the variants are aligned with those of antibody LAY. Residues not shown were those of the corresponding position in antibody LAY.

All of the additional heavy chain variants were constructed by replacing DNA restriction endonuclease fragments from plasmid pDA5 with double-stranded oligonucleotide cassettes containing the desired mutations. In each cassette, the nucleotide sequences chosen to encode the protein sequence maintained the codons that were used in the original version, except that some codons were altered to incorporate the amino acid changes and also to introduce a unique restriction endonuclease cleavage site for selection of positive transformants.

To construct h25D2H-2, an oligonucleotide cassette comprising oligonucleotides designated 3112 (SEQ ID NO: 55) and 3116 (SEQ ID NO: 56) containing a "silent" *Nhe*I site was used to replace the *Bam*HI/*Sma*I DNA fragment in pDA5, and the new plasmid was designated pKM21. To create h25D2H-3,

- 49 -

the DNA of pKM21 was cleaved with *NheI* and *SmaI*, releasing CDR 1. This *NheI/SmaI* CDR 1 DNA fragment was then replaced with an oligonucleotide cassette comprising oligonucleotides 3117 (SEQ ID NO: 57) and 3118 (SEQ ID NO: 58), to generate pKM23 containing the h25D2H-3 sequence.

Vectors pKM21 and pKM23 were cleaved with *SalI* and *SmaI*, and the fragments containing the altered CDR 1 sequences were isolated and subsequently used to replace the corresponding CDR 1 DNA fragment in vector pSh25H-1. The resulting expression vectors encoding the h25D2H-2 and h25D2H-3 heavy chains were designated pSh25H-2 and pSh25H-3, respectively.

To construct the h25D2H-4 coding sequence, plasmid pKM23 was cleaved with *MscI* and *PstI* to release a DNA fragment encompassing CDR 2. Plasmid pKM21 was similarly prepared with *MscI* and *PstI* to construct the h25D2H-5 coding sequence. An oligonucleotide cassette comprising oligonucleotides 3119 (SEQ ID NO: 59) and 3120 (SEQ ID NO: 60) encompassing the altered CDR 2 was inserted between the *MscI* and *PstI* sites in both plasmids, to generate h25D2H-4 and h25D2H-5, respectively.

The resulting plasmids were digested with *SacI* and treated with T4 DNA polymerase under conditions that left flush ends. The coding regions for the h25D2H-4 and h25D2H-5 heavy chains were isolated following *SalI* cleavage and subcloned into vector pSRS which had previously been digested with *SalI* and *SmaI*. The final vectors were designated pSh25H-4 and pSh25H-5, respectively.

30 Expression and Purification of the Humanized Antibodies

All of the humanized antibody DNAs were transfected into COS 7 cells by electroporation, and the medium was replaced with serum-free medium four hours after

- 50 -

transfection. The cells were propagated in serum-free medium for 3 days, after which the medium was harvested. To obtain greater amounts of the humanized antibodies, stable CHO cell lines were established that produced the h25D2-1 and the h25D2-4 antibodies.

The appropriate heavy chain plasmid (pSh25H-1 and pSh25H-4, respectively) was co-transfected with the pKM20 light chain plasmid at a ratio of 10:1 into CHO DXB11 cells. Of approximately 40 clones selected for resistance to hypoxanthine and thymidine starvation, greater than 50% tested positive for h25D2-1 antibody expression in a human IgG4 ELISA assay.

Twelve of the clones producing the greatest amount of antibody h25D2-1 were subjected to methotrexate-mediated DNA amplification. Six of these clones (designated h25D2-1 #1, #7, #15, #17, #18 and #21) were selected for growth in the presence of 100-250 nM methotrexate. The levels of antibodies expressed by these clones was estimated based on ELISA to be about 200-700 ng/10⁶ cells/day. Clone #17 clone was expanded into roller bottle culture to obtain greater quantities of the h25D2-1 antibody for purification and characterization.

Approximately 40 clones transfected with the h25D2-4 plasmids were also selected for resistance to hypoxanthine and thymidine starvation. About 30% of these clones tested positive for antibody expression in a human IgG4 ELISA assay. The positive clones were grown in the presence of 5 nM methotrexate. The antibody level of one of the h25D2-4 clones (designated clone #7A) was estimated by IgG4 ELISA to be about 50-100 ng/10⁶ cells/day. This clone was expanded into roller bottle culture to produce greater quantities of antibody h25D2-4 for purification and characterization.

Serum-free conditioned medium containing antibodies produced by CHO cell clones in roller bottle culture was harvested continuously as described above. Antibodies in

- 51 -

the conditioned medium were partially purified by protein G-SEPHAROSE® chromatography. Analysis of the antibodies by reducing SDS-PAGE showed a high degree of purity (at least about 90 %). Analysis of the antibodies by a series of ELISA assays that showed that they contained both human κ and $\gamma 4$ constant regions.

Example III Antibody Characterization

Affinity Constants

All five variants of the humanized heavy chain gene were independently co-transfected into COS 7 cells with the pKM20 light chain vector. The serum-free conditioned medium was harvested after 72 hours and concentrated. Affinity constants were determined as described above, with the results shown in Table 3.

<u>Table 3</u>				
	Antibody	Source*	Coating Antibody	Apparent K_d
20	h25D2-1	COSCM	α hIgG4 Fc	4 nM
	h25D2-2	COSCM	α hIgG4 Fc	29 nM
	h25D2-3	COSCM	α hIgG4 Fc	5 nM
	h25D2-4	COSCM	α hIgG4 Fc	5 nM
25	h25D2-5	COSCM	α hIgG4 Fc	31 nM
	25D2	Purified	α rat IgG Fc	1 nM

* COS CM= COS cell conditioned medium.

30

- 52 -

As shown in Table 3, the affinities of humanized antibodies h25D2-1, h25D2-3 and h25D2-4 for binding to human IL-4 were similar to that of the native rat 25D2 antibody. The affinities of antibodies h25D2-2 and h25D2-5 antibodies were lower.

Competitive Binding Analysis

To further characterize humanized antibody variants h25D2-1 and h25D2-4, competitive binding assays with the humanized antibodies and rat antibody 25D2 were performed as described above. The results showed that at room temperature antibody h25D2-1 was 3-fold less effective than antibody 25D2 in competing with antibody 25D2 for binding to ^{125}I -hIL-4. Antibody h25D2-4 was about 100-fold less effective than antibody 25D2 in the same assay. When the same assays were carried out at 4°C, however, humanized antibody h25D2-1 was as effective in the competition assay as the native antibody, and antibody h25D2-4 was only 2-fold less effective.

Receptor Binding Inhibition

Humanized antibodies h25D2-1 and h25D2-4 antibodies were assayed as described above for the ability to inhibit binding of radiolabeled hIL-4 to recombinant hIL-4 receptors expressed on the Jijoye CJ cell line. With a constant concentration of the radiolabeled hIL-4, the concentration of antibodies h25D2-1 and h25D2-4 required to cause 50% inhibition of receptor binding (IC_{50}) was calculated to be 0.5-1.0 and 1.0-2.0 nM, respectively. The IC_{50} for the native 25D2 antibody was determined to be 0.5-1.0 nM.

30

- 53 -

Inhibition of Germline Epsilon Promoter Activity

Jijoye C12 cells contain multiple endogenous copies of a human growth hormone reporter gene operably linked to a germline ϵ transcript promoter. This promoter is inducible by IL-4 [Rothman *et al.*, J. Exp. Med. 168:2385 (1988)].

To determine whether antibodies h25D2-1 and h25D2-4 could block induction by human IL-4 of the germline ϵ promoter, assays were carried out using Jijoye C12 cells as described above. IC₅₀ values for antibodies h25D2-1 and h25D2-4 were found to be about 120 and 600 pM, respectively, compared to a range of 20-40 pM observed for wild-type antibody 25D2.

Example IV High Affinity Humanized Antibodies

15

Strategy

The light and heavy chains of humanized antibody h25D2-1 described above were selected for further modification to construct a markedly superior humanized monoclonal antibody designated h25D2-9. The light and heavy chains of the starting antibody are designated above as h25D2L-1 and h25D2H-1, respectively, and will be referred to as such below.

Initially, humanized antibody versions designated h25D2-7 and h25D2-8 were designed that contained *inter alia* a modification of heavy chain h25D2H-1 in which the alanine residue at position 97 (see SEQ ID NO: 32) was replaced with a valine residue present in the rodent antibody at that position. This modified heavy chain in versions h25D2-7 and h25D2-8 was combined with light chains h25D2L and h25D2L-1, respectively. The desired performance characteristics, however, were not obtained with these antibodies.

- 54 -

To make antibody h25D2-9, the framework regions of the parental LAY heavy and light chain sequences were inspected for residues differing from the human consensus residues for the heavy chain subgroup III and kappa light chain subgroup I, as defined by Kabat, *supra*.

This analysis differed from the method employed by Adair *et al.* (International Patent Application Publication No. WO 91/09967) in that (a) all positions at which the sequence had been altered to the rodent residue to form h25D2-1 were excluded from further consideration, and (b) consensus subgroup residues were considered instead of overall consensus residues.

Using information obtained from the framework sequence inspections, humanized antibody h-25D2-9 was designed by changing several of the non-consensus h25D2-1 residues to either the corresponding 25D2 rodent antibody residue or to the human consensus residue, employing the method of Adair *et al.*, *supra*, modified as described above. Nine heavy and five light chain residues of antibody h25D2-1 were thus changed in the design of antibody h25D2-9.

A summary of the changes made, including the relevant Kabat positions and residues in the various constructs, antibody LAY and the original rodent antibody 25D2, is shown in Table 4.

- 55 -

Table 4

5	Kabat No.	h25D2-9	h25D2-9		25D2	LAY	Subgroup
			Rationale	h25D2-1			Human
							Consensus
<i>Heavy Chain Variable Domain</i>							
	1	E	Rodent	E	E	A	E
10	5	V	Consensus	L	V	L	V
	49	A	Rodent	A	A	A	S
	72	D	Rodent	D	D	N	D
	82B	S	Consensus	G	S	G	S
	83	R	Consensus	Q	R	Q	R
15	86	D	Consensus	V	D	V	D
	87	T	Rodent	S	T	S	T
	89	V	Consensus	I	T	I	V
<i>Light Chain Variable Domain</i>							
20	13	A	Consensus	V	A	V	A
	42	K	Consensus	L	E	L	K
	73	L	Consensus	F	L	F	L
	83	F	Consensus	I	V	I	F
25	106	I	Consensus	V	L	V	I

Standard single-letter abbreviations are used to represent the amino acid residues.

30

The rationale for inclusion of human consensus or rodent is also provided in Table 4. Note that four heavy chain (Kabat positions 1, 49, 72, and 87) and no light chain residues were included as rodent. Five heavy chain (Kabat positions 5, 82B, 83, 86, and 89) and five light chain (Kabat positions 13,

35

- 56 -

42, 73, 83, and 106) residues were included as human consensus. At heavy chain positions 1, 5, 72, 82B, 83, 86, and 87 and light chain positions 13 and 73, rodent and human consensus residues were identical. The rationale for inclusion in h25D2-9 was consensus for all of these positions, with the exception of heavy chain positions 1, 72, and 87, which were included as rodent.

Construction

10

Light Chain

A Bluescribe plasmid containing the *EcoRI/KpnI* fragment 1 (used in the construction of light chain h25D2L described above) inserted between the *EcoRI* and *KpnI* sites served as the starting plasmid. Four oligonucleotide cassettes comprising eight paired synthetic oligonucleotides were consecutively inserted into the vector to generate a plasmid designated h25D2-9 VL.

20 The designations of these oligonucleotides (shown paired as in the cassettes), followed in parentheses by the corresponding sequence identification numbers, were as follows:

25 3866 (SEQ ID NO: 61)
3867 (SEQ ID NO: 62)

3944 (SEQ ID NO: 63)
3945 (SEQ ID NO: 64)

30 3966 (SEQ ID NO: 65)
3967 (SEQ ID NO: 66)

3979 (SEQ ID NO: 67)
3980 (SEQ ID NO: 68)

- 57 -

During the construction, silent restriction endonuclease cleavage sites were added to the cassettes for identification of recombinant plasmids. Initially, an *EcoRI/BstEII* fragment in the starting plasmid was replaced with the cassette comprising
5 oligonucleotide pair 3866/3867. The result was replacement of the valine residue at position 13 of light chain h25D2-1 (see SEQ ID NO: 27) with an alanine residue and introduction of a silent *HindIII* site, and the construct was designated pKM45.

Next, the cassette comprising oligonucleotide pair
10 3944/3945 was inserted between the *KpnI* and *XbaI* sites of pKM45. The resulting construct, designated pKM47, contained a lysine residue at position 42 instead of the leucine residue present at that position in light chain h25D2L-1 and a silent *XhoI* site.

15 The cassette comprising oligonucleotide pair 3966/3967 was then inserted between the *XbaI* and *PstI* sites of pKM47 to generate pKM49 which contained a leucine residue at position 73 instead of the phenylalanine present at that position in light chain h25D2L-1, and a silent *XmnI* site.

20 Finally, cassette comprising oligonucleotide pair 3979/3980 was inserted between the *PstI* and *SphI* sites of pKM49 to yield pKM50. Plasmid pKM50 contained a phenylalanine residue at position 83 instead of the isoleucine residue at that position in h25D2L-1, and a silent *SnaBI* site.
25 It also contained an *MscI* site to facilitate further cloning manipulations.

The construct was further modified to contain an isoleucine residue at position 105, instead of the valine residue present at that position in h25D2L-1. To make this change, the
30 Bluescript vector containing the h25D2L-1 coding sequence was subjected to single-stranded mutagenesis (Sambrook *et al.*, 1989, in *Molecular Cloning*; Cold Spring Harbor Press; Vol. I p. 4.48 and Vol. II p. 15.63-15.65) using an oligonucleotide designated 3974 (sequence defined by
35 SEQ ID NO: 69). This oligonucleotide produced the desired

- 58 -

substitution and resulted in deletion of two *StyI* sites, thereby facilitating selection of the mutant plasmids. The resulting plasmid was designated pKM51.

5 The *SalI-MscI* fragment of pKM51 was replaced with the corresponding fragment from pKM50 to yield plasmid pKM52. This plasmid contained the entire coding region of the h25D2-9 light chain and included, in summary, the following changes with respect to the h25D2-1 light chain: V13A, L42K, F73L, I83F, and V105I.

10 The complete light chain variable region sequence is shown in SEQ ID NO: 70 of the Sequence Listing, together with the sequence of a secretory leader.

To construct a mammalian expression vector, plasmid pKM52 containing the h25D2-9 light chain sequence was
15 cleaved at the 3' end with *SpeI* and treated with the Klenow fragment of DNA polymerase under conditions that left flush ends. The h25D2-9 DNA fragment was obtained after cleavage at the 5' end with *SalI* and was ligated to vector pDSRS which had previously been digested with *SalI* and *SmaI*. The
20 completed expression vector, designated pKM53, contained the entire coding region for the h25D2L-9 light chain, including the signal peptide and human kappa constant region.

Heavy Chain

25 Beginning with plasmid pDA5 described above, heavy chain h25D2-1 of antibody h25D2-1 (see SEQ ID NO: 32) was modified by restriction cleavage and the successive introduction of four oligonucleotide cassettes which comprised
30 eight paired synthetic oligonucleotides. Silent restriction endonuclease cleavage sites were added to the cassettes for identification of recombinant plasmids.

- 59 -

The designations of these oligonucleotides (shown paired as in the cassettes), followed in parentheses by the corresponding sequence identification numbers, were as follows:

- 5 3592 (SEQ ID NO: 71)
 3593 (SEQ ID NO: 72)
- 3850 (SEQ ID NO: 73)
 3851 (SEQ ID NO: 74)
- 10 3711 (SEQ ID NO: 75)
 3712 (SEQ ID NO: 76)
- 3848 (SEQ ID NO: 77)
15 3849 (SEQ ID NO: 78)

Modification of the heavy chain h25D2-1 of antibody h25D2-1 was initiated by replacing the *MscI/PstI* fragment of pDA5 with a cassette comprising oligonucleotide pair 3592/3593. This incorporated an N73D and N77S change, as well as a silent *XbaI* site. The resulting plasmid was designated pKM37. A *SalI/KpnI* fragment (encompassing amino acid residues 1-113) was isolated from pKM37 and subcloned into a Bluescript vector, to facilitate further cloning manipulations. This vector was designated pKM39.

25 The oligonucleotide cassette comprising oligonucleotide pair 3850/3851 was inserted between the *BamHI* and *SacII* sites (*SacII* located in vector) of pKM39. The resulting plasmid, termed pKM44, contained L5V, N73D and N77S changes.

30 Plasmid pKM39 served as the starting plasmid for incorporation of the last two cassettes. Initially, a *SmaI* fragment encompassing a *PstI* site in the vector was removed from pKM39 to facilitate cloning. The cassette comprising oligonucleotide pair 3711/3712 was used to replace the

- 60 -

corresponding fragment in the V_H region of the vector. The final construct was designated pKM41 and contained the A97V change and a silent *NruI* site that was used in subsequent cloning manipulations.

5 Next, the cassette comprising oligonucleotide pair 3848/3849 was inserted between the *PstI* and *NruI* sites of pKM41. The resulting construct, designated pKM43, contained an A97V change as well as G85S, Q87R, V90D, S91T and I93V changes. The *KpnI/MscI* fragment of pKM43 was isolated and
10 used to replace the corresponding fragment of pKM44 (pKM44 contained the N73D, N77S and L5V changes). The resulting plasmid, designated pKM46, contained the complete h25D2-9 V_H region.

15 The complete heavy chain variable region sequence is shown in SEQ ID NO: 79 of the Sequence Listing, together with the sequence of a secretory leader.

20 A *Sall/KpnI* fragment (encompassing amino acid residues 1-113 of the heavy chain) served to replace the corresponding fragment in the pSh25D2H-1 expression vector, and the final expression vector for the h25D2-9 heavy chain was designated pSh25D2H-9.

25 The complete light and heavy chain amino acid sequences of antibody h25D2-9 are defined in the Sequence Listing by SEQ ID NO: 80 and SEQ ID NO: 81, respectively. The sequences show the putative amino-terminal residues for the mature forms of the antibody chains produced following cleavage of the secretory leaders. Again, many other well known leaders could have been used instead of the ones actually employed to illustrate this invention.

30

Antibody Expression Levels

35 COS cells were transfected as described above with 10 µg each of either plasmids pKM53 (for antibody h25D2-9 light chain) and pSh25D2H-9 (for antibody h25D2-9 heavy

- 61 -

chain) or plasmids pKM20 (for antibody h25D2-1 light chain) and pSh25D2H-1 (for antibody h25D2-1 heavy chain). Following a four-day incubation in medium containing 1% fetal calf serum to permit antibody secretion, samples of medium
5 from the COS cells were subjected to ELISA essentially as described above to determine the levels of expression of humanized antibodies h25D2-1, the best of the prior humanized antibodies in terms of performance characteristics, and h25D2-9.

10 It was thereby found that humanized antibody h25D2-1 was produced at a level of 10-20 ng/ml of medium. In contrast, antibody h25D2-9 was produced at a level of 100 ng/ml, a five to ten fold increase over that of h25D2-1.

15 Competition Assay

A plate competition assay was carried out as described above using ^{125}I -hIL-4, immobilized rat antibody 25D2, and varying levels of free antibodies 25D2, h25D2-1 or h25D2-9.
20 The results of this assay, which was carried out both at 4°C and at room temperature (about 22°C), are shown in Figure 2.

As can be seen from Figure 2, both humanized antibodies were about as effective as rodent antibody 25D2 in competing for binding to the ^{125}I -hIL-4 at 4°C. At room temperature,
25 however, a concentration of antibody h25D2-1 that was more than twice that of antibody h25D2-9 was required to produce a comparable, fifty percent inhibition of the binding of the ^{125}I -hIL-4 to the immobilized antibody. Thus antibody h25D2-1 was less active than antibody h25D2-9 at the higher
30 temperature.

Bioassay

To compare the abilities of rodent antibody 25D2
35 and humanized antibodies h25D2-1 and h25D2-9 to inhibit

- 62 -

induction of human growth hormone in the germline epsilon reporter assay, the assay employing the Jijoye C12 cell line described above was carried out on varying amounts of all three antibodies. The results are shown in Figure 3, where
5 it is evident that although the 25D2 and h25D2-9 antibodies were similar in activity. In contrast, an approximately five-fold higher concentration of antibody h25D2-1 was required to produce a comparable, fifty percent inhibition in the assay.

10 Hybridoma Deposit

Hybridoma MP4.25D2.11 was deposited September 1, 1988 with the American Type Culture Collection, Rockville, MD, USA (ATCC), under accession number ATCC HB 9809. This deposit was made under conditions as
15 provided under ATCC's agreement for Culture Deposit for Patent Purposes, which assures that the deposit will be made available to the US Commissioner of Patents and Trademarks pursuant to 35 USC 122 and 37 CFR 1.14 and will be made available to the public upon issue of a U.S. patent and requires
20 that the deposit be maintained. Availability of the deposited strain is not to be construed as a license to practise the invention in contravention of the rights granted under the authority of any government in accordance with its patent laws.

25 Many modifications and variations of this invention can be made without departing from its spirit and scope, as will become apparent to those skilled in the art. The specific embodiments described herein are offered by way of example only, and the invention is to be limited only by the terms of
30 the appended claims.

- 63 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- 5 (i) APPLICANT (for all designated States
except the United States of America):
(A) NAME: Schering Corporation
(B) STREET: 2000 Galloping Hill Road
10 (C) CITY: Kenilworth
(D) STATE: New Jersey
(E) COUNTRY: U.S.A.
(F) POSTAL CODE (ZIP): 07033-0530
(G) TELEPHONE: 908-298-2906
15 (H) TELEFAX: 908-298-5388
(I) TELEX:
- (i) APPLICANT (for the United States of America only):
Dalie, Barbara
20 Miller, Kenneth
Murgolo, Nicholas
Tindall, Stephen
- (ii) TITLE OF INVENTION: Humanized Monoclonal
25 Antibodies Against Human
Interleukin-4
- (iii) NUMBER OF SEQUENCES: 81
- 30 (iv) CORRESPONDENCE ADDRESS:
- (A) ADDRESSEE: Schering-Plough Corporation
- (B) STREET: 2000 Galloping Hill Road
35

- 6 4 -

(C) CITY: Kenilworth

(D) STATE: New Jersey

5 (E) COUNTRY: USA

(F) ZIP: 07033-0530

(v) COMPUTER READABLE FORM:

10

(A) MEDIUM TYPE: Floppy disk

(B) COMPUTER: Apple Macintosh

15 (C) OPERATING SYSTEM: Macintosh 6.0.5

(D) SOFTWARE: Microsoft Word 5.1a

(vi) CURRENT APPLICATION DATA:

20

(A) APPLICATION NUMBER:

(B) FILING DATE:

25 (C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US 08/208886

30

(B) FILING DATE: 10-MAR-1994

(viii) ATTORNEY/AGENT INFORMATION:

35 (A) NAME: Dulak, Norman C.

- 65 -

(B) REGISTRATION NUMBER: 31,608

(C) REFERENCE/DOCKET NUMBER: JB0429K

5

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (908) 298-2906

10 (B) TELEFAX: (908) 298-5388

(C) TELEX:

(2) INFORMATION FOR SEQ ID NO: 1:

15

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 363 base pairs

20 (B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

```

30 GAA CTG CAG TTG GTA GAA AGT GGG GGA GGT CTG GTG CAG CCT GGA AGG 48
   Glu Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg
      5                      10                      15

   TCT CTG AAA CTA TCC TGT GTG GCC TCT GGA TTC TCA TTC AGA AGT TAC 96
   Ser Leu Lys Leu Ser Cys Val Ala Ser Gly Phe Ser Phe Arg Ser Tyr
      20                      25                      30

35 TGG ATG ACC TGG GTC CGT CAG GCT CCA GGG AAG GGG CTG GAG TGG ATT 144
   Trp Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
      35                      40                      45
```

- 66 -

GCA TCC ATT AGT ATT TCT GGT GAT AAC ACG TAC TAT CCA GAC TCT GTG 192
 Ala Ser Ile Ser Ile Ser Gly Asp Asn Thr Tyr Tyr Pro Asp Ser Val
 50 55 60

5 AGG GGC CGA TTC ACT ATC TCC AGG GAT GAT GCA AAA AGC ATC CTA TAC 240
 Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ala Lys Ser Ile Leu Tyr
 65 70 75 80

10 CTT CAA ATG AAC AGT CTG AGG TCT GAG GAC ACG GCC ACT TAT TAC TGT 288
 Leu Gln Met Asn Ser Leu Arg Ser Glu Asp Thr Ala Thr Tyr Tyr Cys
 85 90 95

15 GTA AGA GAT CCC TAT TAC TTC AGT GGC CAC TAC TTT GAT TTC TGG GGC 336
 Val Arg Asp Pro Tyr Tyr Phe Ser Gly His Tyr Phe Asp Phe Trp Gly
 100 105 110

CAA GGA GTC ATG GTC ACA GTC TCC TCA 363
 Gln Gly Val Met Val Thr Val Ser Ser
 115 120

20

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

25 (A) LENGTH: 321 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

30

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

35 GAT ATC CAG ATG ACA CAG AGT CCT TCA CTC CTG TCT GCA TCT GTG GGA 48
 Asp Ile Gln Met Thr Gln Ser Pro Ser Leu Leu Ser Ala Ser Val Gly
 5 10 15

40 GAC AGA GTC ACT CTC AAC TGC AAA GCA AGT CAG AAT ATT TAT AAG AAT 96
 Asp Arg Val Thr Leu Asn Cys Lys Ala Ser Gln Asn Ile Tyr Lys Asn
 20 25 30

- 67 -

	TTA GCC TGG TAT CAG CAA AAG CTT GGA GAA GCT CCC AAG TTC CTG ATT	144
	Leu Ala Trp Tyr Gln Gln Lys Leu Gly Glu Ala Pro Lys Phe Leu Ile	
	35 40 45	
5	TTT AAT GCA AAA AGT TTG GAG ACG GGC GTC CCA TCA AGG TTC AGT GGC	192
	Phe Asn Ala Lys Ser Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly	
	50 55 60	
10	AGT GGA TCT GGC ACA GAT TTC ACA CTC ACA ATC AGC AGC CTA CAG CCT	240
	Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro	
	65 70 75 80	
15	GAA GAT GTT GCC ACA TAT TTC TGC CAA CAA TAT TAT AGC GGG TGG ACG	288
	Glu Asp Val Ala Thr Tyr Phe Cys Gln Gln Tyr Tyr Ser Gly Trp Thr	
	85 90 95	
	TTC GGT GGA GGC ACC AAG CTG GAA TTG AAA CGG	321
	Phe Gly Gly Gly Thr Lys Leu Glu Leu Lys Arg	
	100 105	

20

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

25 (A) LENGTH: 17 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

30

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

35 CGATGCACAA GTGCGAT 17

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

40

- 68 -

(A) LENGTH: 15 base pairs

(B) TYPE: nucleic acid

5 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

10

ATCGCACTTG TGCAT 15

(2) INFORMATION FOR SEQ ID NO: 5:

15 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 46 base pairs

(B) TYPE: nucleic acid

20 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

25

GCACTAGTTC TAGAAGGCCA AGAGGGGCCA CTGACTCTGG GGTCAT 46

(2) INFORMATION FOR SEQ ID NO: 6:

30 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 51 base pairs

(B) TYPE: nucleic acid

35

(C) STRANDEDNESS: single

- 69 -

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

5

GCGCGGCCGC GARYTNCARY TNGTNGARWS NGGNGGNGGN CTNGTNCARC C 51

(2) INFORMATION FOR SEQ ID NO: 7:

10 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 51 base pairs

(B) TYPE: nucleic acid

15

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

20

GCACTAGTTC TAGATTGGGT CTAACACTCA TTCCTGTTGA AGCTCTTGAC G 51

(2) INFORMATION FOR SEQ ID NO: 8:

25 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 33 base pairs

(B) TYPE: nucleic acid

30

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

- 70 -

GCGCGGCCGC GAYATHCARA TGACNCARAG YCC 33

(2) INFORMATION FOR SEQ ID NO: 9:

5

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

10 (B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

GGAAGGTCTC TGAACTATC 20

20 (2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 16 base pairs

25

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

30 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

AGACAGAGTC ACTCTC 16

35

(2) INFORMATION FOR SEQ ID NO: 11:

- 7 1 -

(i) SEQUENCE CHARACTERISTICS:

5 (A) LENGTH: 13 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

10 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

CCTTCAAATG AAC 13

15

(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:

20 (A) LENGTH: 13 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

25

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

30 GTTCATTGA AGG 13

(2) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERISTICS:

35

- 72 -

(A) LENGTH: 18 base pairs

(B) TYPE: nucleic acid

5 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

10

GCCTGAAGAT GTTGCCAC 18

(2) INFORMATION FOR SEQ ID NO: 14:

15 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 17 base pairs

(B) TYPE: nucleic acid

20 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

25

ATTAACCCTC ACTAAAG 17

(2) INFORMATION FOR SEQ ID NO: 15:

30 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 17 base pairs

(B) TYPE: nucleic acid

35

- 73 -

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

AATACGACTC ACTATAG 17

(2) INFORMATION FOR SEQ ID NO: 16:

10

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 390 base pairs

15 (B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

GAATTCGCCG CCACC ATG GGA TGG AGC TGT ATC ATC CTC TTC TTG GTA 48
 Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val
 -15 -10

25

GCA ACA GCT ACA GGT GTC CAC TCC GAT ATC CAG ATG ACC CAG AGC CCA 96
 Ala Thr Ala Thr Gly Val His Ser Asp Ile Gln Met Thr Gln Ser Pro
 -5 1 5

30

AGC AGC CTG AGC GTG AGC GTG GGT GAC CGC GTG ACC ATC ACC TGC AAG 144
 Ser Ser Leu Ser Val Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys
 10 15 20

35

GCC AGC CAG AAC ATC TAC AAG AAC CTG GCC TGG TAC CAG CAG AAG CCA 192
 Ala Ser Gln Asn Ile Tyr Lys Asn Leu Ala Trp Tyr Gln Gln Lys Pro
 25 30 35 40

40

GGC CTG GCC CCA AAG TTC CTG ATC TTC AAC GCC AAG AGC CTG GAG ACC 240
 Gly Leu Ala Pro Lys Phe Leu Ile Phe Asn Ala Lys Ser Leu Glu Thr
 45 50 55

- 74 -

GGC GTG CCA TCT AGA TTC AGC GGC AGC GGC AGC GGC ACC GAC TTC ACC 288
 Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
 60 65 70

5 TTC ACC ATC AGC AGC CTG CAG CCA GAG GAC ATC GCC ACC TAC TAC TGC 336
 Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys
 75 80 85

10 CAG CAG TAC TAC AGC GGC TGG ACC TTT GGC CAA GGC ACC AAG GTG GAG 384
 Gln Gln Tyr Tyr Ser Gly Trp Thr Phe Gly Gln Gly Thr Lys Val Glu
 90 95 100

GTG AAG 390
 15 Val Lys
 105

(2) INFORMATION FOR SEQ ID NO: 17:

20 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 72 base pairs

(B) TYPE: nucleic acid

25

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

GAACAAAAGC TTGACATCCA GATGACCCAG AGCCCAAGCA GCCTGAGCGT GAGCGTGGGT 60
 GACCGCGTGA CC 72

35 (2) INFORMATION FOR SEQ ID NO: 18:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 73 base pairs

- 75 -

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

5

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

1 0 GAGCTCGGTA CCAGGCCAGG TTCTGTAGA TGTTCTGGCT GGCCTTGCAG GTGATGGTCA 60
CGCGGTCACC CAC 73

(2) INFORMATION FOR SEQ ID NO: 19:

1 5 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 105 base pairs

(B) TYPE: nucleic acid

2 0

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

2 5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

GGTACCGGTC CGGAATTCGC CGCCACCATG GGATGGAGCT GTATCATCCT CTTCTTGGTA 60
GCAACAGCTA CAGGTGTCCA CTCCGATATC CAGATGACCC AGAGC 105

3 0 (2) INFORMATION FOR SEQ ID NO: 20:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 36 base pairs

3 5

- 76 -

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

5 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

CTGCTGGTAC CAGGCCAGGT TCTTGTAGAT GTTCTG 36

10

(2) INFORMATION FOR SEQ ID NO: 21:

(i) SEQUENCE CHARACTERISTICS:

15 (A) LENGTH: 80 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

20

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

25 TCCCCGGGTA CCAGCAGAAG CCAGGCCTGG CCCCAAAGTT CCTGATCTTC AACGCCAAGA 60
GCCTGGAGAC CGGCGTGCCA 80

(2) INFORMATION FOR SEQ ID NO: 22:

30 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 84 base pairs

(B) TYPE: nucleic acid

35

- 77 -

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

GTTCGACCTGC AGGCTGCTGA TGGTGAAGGT GAAGTCGGTG CCGCTGCCGC TGCCGCTGAA 60
TCTAGATGGC ACGCCGGTCT CCAG 84

10 (2) INFORMATION FOR SEQ ID NO: 23:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 68 base pairs

15

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

20

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

ACCATCAGCA GCCTGCAGCC AGAGGACATC GCCACCTACT ACTGCCAGCA GTACTACAGC 60
25 GGCTGGAC 68

(2) INFORMATION FOR SEQ ID NO: 24:

(i) SEQUENCE CHARACTERISTICS:

30

(A) LENGTH: 74 base pairs

(B) TYPE: nucleic acid

35

(C) STRANDEDNESS: single

- 78 -

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

5

CAGAGTTTAG AATTCACTCA CGCTTCACCT CCACCTTGGT GCCTTGGCCA AAGTCCAGC 60
CGCTGTAGTA CTGC 74

(2) INFORMATION FOR SEQ ID NO: 25:

10

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 33 base pairs

15

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

GTCGAATTCT CAACACTCTC CCCTGTTGAA GCT 33

25 (2) INFORMATION FOR SEQ ID NO: 26:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 59 base pairs

30

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

35

(D) TOPOLOGY: linear

- 79 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

5 GTTTTGGCCA AGGCACCAAG GTGGAGGTGA AGACTGTGGC TGCACCATCT GTCTTCATC 59

(2) INFORMATION FOR SEQ ID NO: 27:

(i) SEQUENCE CHARACTERISTICS:

10 (A) LENGTH: 393 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

15

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

20 GAATTCGCCG CCACC ATG GGA TGG AGC TGT ATC ATC CTC TTC TTG GTA 48
Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val
-15 -10

25 GCA ACA GCT ACA GGT GTC CAC TCC GAT ATC CAG ATG ACC CAG AGC CCA 96
Ala Thr Ala Thr Gly Val His Ser Asp Ile Gln Met Thr Gln Ser Pro
-5 1 5

30 AGC AGC CTG AGC GTG AGC GTG GGT GAC CGC GTG ACC ATC ACC TGC AAG 144
Ser Ser Leu Ser Val Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys
10 15 20

GCC AGC CAG AAC ATC TAC AAG AAC CTG GCC TGG TAC CAG CAG AAG CCA 192
Ala Ser Gln Asn Ile Tyr Lys Asn Leu Ala Trp Tyr Gln Gln Lys Pro
25 30 35 40

35 GGC CTG GCC CCA AAG CTG CTG ATC TAC AAC GCC AAG AGC CTG GAG ACC 240
Gly Leu Ala Pro Lys Leu Leu Ile Tyr Asn Ala Lys Ser Leu Glu Thr
45 50 55

40 GGC GTG CCA TCT AGA TTC AGC GGC AGC GGC AGC GGC ACC GAC TTC ACC 288
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
60 65 70

- 80 -

TTC ACC ATC AGC AGC CTG CAG CCA GAG GAC ATC GCC ACC TAC TAC TGC 336
 Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys
 75 80 85

5

CAG CAG TAC TAC AGC GGC TGG ACC TTT GGC CAA GGC ACC AAG GTG GAG 384
 Gln Gln Tyr Tyr Ser Gly Trp Thr Phe Gly Gln Gly Thr Lys Val Glu
 90 95 100

10

GTG AAG CGC 393
 Val Lys Arg
 105

(2) INFORMATION FOR SEQ ID NO: 28:

15

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 39 base pairs

20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

AAGCCAGGCC TGGCCCCAAA GCTGCTGATC TACAACGCC 39

30

(2) INFORMATION FOR SEQ ID NO: 29:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15 base pairs

35

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

- 81 -

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:

5

TGGCTGCAGG CTGCT 15

(2) INFORMATION FOR SEQ ID NO: 30:

10 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 45 base pairs

(B) TYPE: nucleic acid

15

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:

ACCTTTGGCC AAGGCACCAA GGTGGAGGTG AAGCGCACTG TGGCT 45

(2) INFORMATION FOR SEQ ID NO: 31:

25

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

30 (B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:

TCTAGAACTA GTGGATCC 18

5 (2) INFORMATION FOR SEQ ID NO: 32:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 435 base pairs

10

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

15 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:

20	GTCGACGCCG	CCACC	ATG	GGA	TGG	AGC	TGT	ATC	ATC	CTC	TTC	TTG	GTA	48
			Met	Gly	Trp	Ser	Cys	Ile	Ile	Leu	Phe	Leu	Val	
							-15					-10		
25	GCA ACA	GCT ACA	GGT GTC	CAC TCC	GAG GTG	CAG CTG	CTG CTG	GAG AGC	GGC	96				
	Ala Thr	Ala Thr	Gly Val	His Ser	Glu Val	Gln Leu	Leu Leu	Glu Ser	Gly					
		-5			1		5							
30	GGC GGC	CTG GTG	CAG CCA	GGC GGA	TCC CTG	CGC CTG	AGC TGC	GCC GCC	144					
	Gly Gly	Leu Val	Gln Pro	Gly Gly	Ser Leu	Arg Leu	Ser Cys	Ala Ala						
	10			15		20								
35	AGC GGC	TTC AGC	TTC CGC	AGC TAC	TGG ATG	ACC TGG	GTG CGC	CAG GCC	192					
	Ser Gly	Phe Ser	Phe Arg	Ser Tyr	Trp Met	Thr Trp	Val Arg	Gln Ala						
	25		30			35		40						
40	CGC GGC	AAG GGC	CTG GAG	TGG GTG	GCC AGC	ATC AGC	ATC AGC	GGC GAC	240					
	Pro Gly	Lys Gly	Leu Glu	Trp Val	Ala Ser	Ile Ser	Ile Ser	Gly Asp						
			45		50			55						
45	AAC ACC	TAC TAC	CCA GAC	AGC GTG	CGC GGC	CGC TTC	ACC ATC	AGC CGC	288					
	Asn Thr	Tyr Tyr	Pro Asp	Ser Val	Arg Gly	Arg Phe	Thr Ile	Ser Arg						
		60			65		70							

- 83 -

AAC GAC AGC AAG AAC ACC CTG TAC CTG CAG ATG AAC GGC CTG CAA GCC 336
 Asn Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Gly Leu Gln Ala
 75 80 85

5 GAG GTG AGC GCC ATC TAC TAC TGC GCC CGC GAC CCA TAC TAC TTC AGC 384
 Glu Val Ser Ala Ile Tyr Tyr Cys Ala Arg Asp Pro Tyr Tyr Phe Ser
 90 95 100

10 GGC CAC TAC TTC GAC TTC TGG GGC CAG GGT ACC CTG GTG ACC GTG AGC 432
 Gly His Tyr Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser
 105 110 115 120

AGC 435
 Ser

15

(2) INFORMATION FOR SEQ ID NO: 33:

(i) SEQUENCE CHARACTERISTICS:

20 (A) LENGTH: 84 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

25

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:

30 ACTAGTGAAT TCGTCGACGC CGCCACCATG GGATGGAGCT GTATCATCCT CTTCTTG GTA 60
 GCAACAGCTA CAGGTGTCCA CTCC 84

(2) INFORMATION FOR SEQ ID NO: 34:

35 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 84 base pairs

- 84 -

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

5 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:

GCAGCTCAGG CGCAGGGATC CGCCTGGCTG CACCAGGCCG CCGCCGCTCT CCAGCAGCTG 60
1 0 CACCTCGGAG TGGACACCTG TAGC 84

(2) INFORMATION FOR SEQ ID NO: 35:

(i) SEQUENCE CHARACTERISTICS:

1 5

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

2 0 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:

2 5

AGCGTCGACG CCGCCACCAT G 21

(2) INFORMATION FOR SEQ ID NO: 36:

3 0 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 80 base pairs

(B) TYPE: nucleic acid

3 5

- 85 -

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36:

GTATCCCCCG GGGCCTGGCG CACCCAGGTC ATCCAGTAGC TCGGAAGCT GAAGCCGCTG 60
GCGGCGCAGC TCAGGCGCAG 80

10 (2) INFORMATION FOR SEQ ID NO: 37:

(i) SEQUENCE CHARACTERISTICS:

15 (A) LENGTH: 79 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

20 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37:

GTATCCCCCG GGCAAGGGCC TGGAGTGGGT GGCCAGCATC AGCATCAGCG GCGACAACAC 60
25 CTACTACCCA GACAGCGTG 79

(2) INFORMATION FOR SEQ ID NO: 38:

(i) SEQUENCE CHARACTERISTICS:

30 (A) LENGTH: 78 base pairs

(B) TYPE: nucleic acid

35 (C) STRANDEDNESS: single

- 86 -

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38:

5

GTAGAACTGC AGGTACAGGG TGTTCTTGCT GTCGTTGCGG CTGATGGTGA AGCGGCCGCG 60
CACGCTGTCT GGGTAGTA 78

(2) INFORMATION FOR SEQ ID NO: 39:

10

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 84 base pairs

15

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39:

AACACCCCTGT ACCTGCAGAT GAACGGCCTG CAAGCCGAGG TGAGCGCCAT CTACTACTGC 60
GCCCCGCGACC CATACTACTT CAGC 84

25

(2) INFORMATION FOR SEQ ID NO: 40:

(i) SEQUENCE CHARACTERISTICS:

30

(A) LENGTH: 60 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

35

- 87 -

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40:

5 GTCACCAGGG TACCCTGGCC CCAGAAGTCG AAGTAGTGGC CGCTGAAGTA GTATGGGTCG 60

(2) INFORMATION FOR SEQ ID NO: 41:

(i) SEQUENCE CHARACTERISTICS:

1 0

(A) LENGTH: 36 base pairs

(B) TYPE: nucleic acid

1 5

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41:

2 0

CTGTACCTGC AGATGAACGG CCTGCAAGCC GAGGTG 36

(2) INFORMATION FOR SEQ ID NO: 42:

2 5 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 60 base pairs

(B) TYPE: nucleic acid

3 0

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

3 5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42:

- 88 -

GGGGAAGACG GATGGGCCCT TGGTGAAGC GCTGCTCAG GTCACCAGG TACCCCTGGCC 60

(2) INFORMATION FOR SEQ ID NO: 43:

5

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 102 base pairs

10 (B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43:

GCTGAATTCG CCGCCACCAT GGGCTGGAGC TGTATCATCC TCTTCTTAGT AGCAACAGCT 60
ACAGGTGTCC ACTCCCAGGT CAAACTGGTA CAAGCTGGAG GT 102

20

(2) INFORMATION FOR SEQ ID NO: 44:

(i) SEQUENCE CHARACTERISTICS:

25 (A) LENGTH: 102 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

30

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44:

35

- 89 -

GCGTACTAGT TAATGATAAC CCAGAGACGA TGCAACTCAG TCGCAGAGAT CTCCTGGCT 60
GTACGACGCC ACCTCCAGCT TGTACCAGTT TGACCTGGGA GT 120

(2) INFORMATION FOR SEQ ID NO: 45:

5

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 86 base pairs

10

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45:

GTCAGACTAG TAATAGTGTG AACTGGATAC GGCAAGCACC TGGCAAGGGT CTGGAGTGGG 60
TTGCACTAAT ATGGAGTAAT GGAGAC 86

20

(2) INFORMATION FOR SEQ ID NO: 46:

(i) SEQUENCE CHARACTERISTICS:

25

(A) LENGTH: 73 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

30

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46:

35

- 90 -

GTACTCTAGA GATTGTGAAT CGAGATTTGA TAGCTGAATT ATAATCTGTG TCTCCATTAC 60
TCCATATTAG TGC 73

(2) INFORMATION FOR SEQ ID NO: 47:

5

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 104 base pairs

10 (B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47:

GCAGAATTCT AGAGACAATT CGAAGAGCAC CCTATACATG CAGATGAACA GTCTGAGAAC 60
TGAAGATACT GCAGTCTACT TCTGTGCTCG TGAGTACTAT GGAT 104

20

(2) INFORMATION FOR SEQ ID NO: 48

(i) SEQUENCE CHARACTERISTICS:

25 (A) LENGTH: 99 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

30

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 48:

35

- 91 -

CTCGTGAGCT CGGGCCCTTG GTCGACGCTG AGGAGACTGT GACTAGGACA CCTTGACCCC 60
AATAGTCGAA ATATCCATAG TACTCACGAG CACAGAAGT 99

(2) INFORMATION FOR SEQ ID NO: 49:

5

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 70 base pairs

10 (B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 49:

GCATCGCGTC GACCAAAGGT CCATCTGTGT TTCCGCTGGC GCCATGCTCC AGGAGCACCT 60
CCGAGAGCAC 70

20

(2) INFORMATION FOR SEQ ID NO: 50:

(i) SEQUENCE CHARACTERISTICS:

25 (A) LENGTH: 79 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

30

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 50:

35

- 92 -

GACAGAATTC AGGTGCTGGA CACGACGGAC ATGGAGGACC ATACTTCGAC TCAACTCTCT 60
TGTCCACCTT GGTGTTGCT 79

(2) INFORMATION FOR SEQ ID NO: 51:

5

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 68 base pairs

10 (B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 51:

ACTGGAATTC CTAGGTGGAC CATCAGTCTT CCTGTTTCCG CCTAAGCCCA AGGACACTCT 60
CATGATCT 68

20

(2) INFORMATION FOR SEQ ID NO: 52:

(i) SEQUENCE CHARACTERISTICS:

25 (A) LENGTH: 51 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

30

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52:

35 CAGGCTGTCG ACTCGAGGCT GACCTTTGGC TTTGGAGATG GTTTTCTCGA T 51

- 93 -

(2) INFORMATION FOR SEQ ID NO: 53:

(i) SEQUENCE CHARACTERISTICS:

5

(A) LENGTH: 38 base pairs

(B) TYPE: nucleic acid

10

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 53:

15

GTAAGCGTCG ACTCGAGAGC CACAGGTGTA CACCCTGC 38

(2) INFORMATION FOR SEQ ID NO: 54:

20 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 40 base pairs

(B) TYPE: nucleic acid

25

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 54:

CGCTAGCGGC CGCTCATTTA CCCAGAGACA GGGAGAGGCT 40

(2) INFORMATION FOR SEQ ID NO: 55:

35

- 9 4 -

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 76 base pairs

5 (B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 55:

GATCCCTGCG CCTGAGCTGC GCCGCTAGCG GCTTCAGCTT CCGCAGCTAC GCCATGAGCT 60
GGGTGCGCCA GGCCCC 76

15

(2) INFORMATION FOR SEQ ID NO: 56:

(i) SEQUENCE CHARACTERISTICS:

20 (A) LENGTH: 72 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

25

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 56:

30 GGGGCCTGGC GCACCCAGCT CATGGCGTAG CTGCGGAAGC TGAAGCCGCT AGCGGCGCAG 60
CTCAGGCGCA GG 72

(2) INFORMATION FOR SEQ ID NO: 57:

35 (i) SEQUENCE CHARACTERISTICS:

- 95 -

(A) LENGTH: 52 base pairs

(B) TYPE: nucleic acid

5

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 57:

CTAGCGGCTT CACCTTCAGC AGCTACTGGA TGACCTGGGT GCGCCAGGCC CC 52

(2) INFORMATION FOR SEQ ID NO: 58:

15

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 48 base pairs

20 (B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 58:

GGGGCCTGGC GCACCCAGGT CATCCAGTAG CTGCTGAAGG TGAAGCCG 48

30 (2) INFORMATION FOR SEQ ID NO: 59:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 100 base pairs

35

- 96 -

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

5 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 59:

CCAGCATCAG CATCAGCGGC GACAACACCT ACTACCCAGA CAGCGTGAAC GGCCGCTTCA 60
10 CCATCTCTAG AAACGACAGC AAGAACACCC TGTACCTGCA 100

(2) INFORMATION FOR SEQ ID NO: 60:

(i) SEQUENCE CHARACTERISTICS:

15

(A) LENGTH: 96 base pairs

(B) TYPE: nucleic acid

20

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 60:

25

GGTACAGGGT GTTCTTGCTG TCGTTTCTAG AGATGGTGAA GCGGCCGTTT ACGCTGTCTG 60
GGTAGTAGGT GTTGTCGCCG CTGATGCTGA TGCTGG 96

(2) INFORMATION FOR SEQ ID NO: 61:

30

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 123 base pairs

35

(B) TYPE: nucleic acid

- 97 -

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 61:

AATTCGTCGA CGCCGCCACC ATGGGATGGA GCTGTATCAT CCTCTTCTTG GTAGCAACAG 60
CTACAGGTGT CCACTCCGAT ATCCAGATGA CCCAGAGCCC ATCAAGCTTG AGCGCGAGCG 120
10 TGG 123

(2) INFORMATION FOR SEQ ID NO: 62:

(i) SEQUENCE CHARACTERISTICS:

15

(A) LENGTH: 124 base pairs

(B) TYPE: nucleic acid

20

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 62:

25

GTCACCCACG CTCGCGCTCA AGCTTGATGG GCTCTGGGTC ATCTGGATAT CGGAGTGGAC 60
ACCTGTAGCT GTTGCTACCA AGAAGAGGAT GATACAGCTC CATCCCATGG TGGCGGCGTC 120
GACG 124

30 (2) INFORMATION FOR SEQ ID NO: 63:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 70 base pairs

35

- 98 -

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

5 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 63:

10 CAGCAGAAGC CAGGCAAGGC CCCAAAGCTG CTGATCTACA ACGCCAAGAG CCTCGAGACC 60
GGCGTGCCAT 70

(2) INFORMATION FOR SEQ ID NO: 64:

(i) SEQUENCE CHARACTERISTICS:

15

(A) LENGTH: 78 base pairs

(B) TYPE: nucleic acid

20

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 64:

25

CTAGATGGCA CGCCGGTCTC GAGGCTCTTG GCGTTGTAGA TCAGCAGCTT TGGGGCCTTG 60
CCTGGCTTCT GCTGGTAC 78

(2) INFORMATION FOR SEQ ID NO: 65:

30

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 58 base pairs

35

(B) TYPE: nucleic acid

- 99 -

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 65:

CTAGATTCAG CGGAAGCGGT TCCGGCACCG ACTTCACCCT CACCATCAGC AGCCTGCA 58

10 (2) INFORMATION FOR SEQ ID NO: 66:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 50 base pairs

15

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

20

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 66:

GGCTGCTGAT GGTGAGGGTG AAGTCGGTGC CGGAACCGCT TCCGCTGAAT 50

25

(2) INFORMATION FOR SEQ ID NO: 67:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 66 base pairs

30

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

35

- 100 -

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 67:

5 GCCAGAGGAC TTCGCTACGT ACTACTGCCA GCAGTACTAC AGCGGCTGGA CCTTTGGCCA 60
AGCATG 66

(2) INFORMATION FOR SEQ ID NO: 68:

10 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 66 base pairs

(B) TYPE: nucleic acid

15

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 68:

CTTGGCCAAA GGTCCAGCCG CTGTAGTACT GCTGGCAGTA GTACGTAGCG AAGTCCTCTG 60
GCTGCA 66

25 (2) INFORMATION FOR SEQ ID NO: 69:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 38 base pairs

30

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

35

(D) TOPOLOGY: linear

- 101 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 69:

CAGTGCCTT TATCTCCACT TTGGTGCCCT GGCCAAAG 38

5

(2) INFORMATION FOR SEQ ID NO: 70:

(i) SEQUENCE CHARACTERISTICS:

10 (A) LENGTH: 393 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

15

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 70:

20 GAATTCGCCG CCACC ATG GGA TGG AGC TGT ATC ATC CTC TTC TTG GTA 48
 Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val
 -15 -10

25 GCA ACA GCT ACA GGT GTC CAC TCC GAT ATC CAG ATG ACC CAG AGC CCA 96
 Ala Thr Ala Thr Gly Val His Ser Asp Ile Gln Met Thr Gln Ser Pro
 -5 1 5

30 TCA AGC TTG AGC GCG AGC GTG GGT GAC CGC GTG ACC ATC ACC TGC AAG 144
 Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys
 10 15 20

GCC AGC CAG AAC ATC TAC AAG AAC CTG GCC TGG TAC CAG CAG AAG CCA 192
 Ala Ser Gln Asn Ile Tyr Lys Asn Leu Ala Trp Tyr Gln Gln Lys Pro
 25 30 35 40

35 GGC AAG GCC CCA AAG CTG CTG ATC TAC AAC GCC AAG AGC CTC GAG ACC 240
 Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asn Ala Lys Ser Leu Glu Thr
 45 50 55

40 GGC GTG CCA TCT AGA TTC AGC GGA AGC GGT TCC GGC ACC GAC TTC ACC 288
 Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
 60 65 70

- 102 -

CTC ACC ATC AGC AGC CTG CAG CCA GAG GAC TTC GCT ACG TAC TAC TGC 336
 Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys
 75 80 85

5

CAG CAG TAC TAC AGC GGC TGG ACC TTT GGC CAG GGC ACC AAA GTG GAG 384
 Gln Gln Tyr Tyr Ser Gly Trp Thr Phe Gly Gln Gly Thr Lys Val Glu
 90 95 100

10

ATA AAG CGC 393
 Ile Lys Arg
 105

(2) INFORMATION FOR SEQ ID NO: 71:

15

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 100 base pairs

20

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 71:

CCAGCATCAG CATCAGCGGC GACAACACCT ACTACCCAGA CAGCGTGCGC GGCCGCTTCA 60
 CCATCTCTAG AGACGACAGC AAGAGCACCC TGTACCTGCA 100

30

(2) INFORMATION FOR SEQ ID NO: 72:

(i) SEQUENCE CHARACTERISTICS:

35

(A) LENGTH: 96 base pairs

(B) TYPE: nucleic acid

- 103 -

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 72:

GGTACAGGGT GCTCTTGCTG TCGTCTCTAG AGATGGTGAA GCGGCCGCGC ACGCTGTCTG 60
GGTAGTAGGT GTTGTCGCCG CTGATGCTGA TGCTGG 96

10 (2) INFORMATION FOR SEQ ID NO: 73:

(i) SEQUENCE CHARACTERISTICS:

15 (A) LENGTH: 120 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

20 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 73:

GGGTCGACGC CGCCACCATG GGATGGAGCT GTATCATCCT CTTCTTGGTA GCAACAGCTA 60
25 CAGGTGTCCA CTCCGAGGTG CAGCTGGTGG AGAGCGGCGG AGGCCTGGTG CAGCCAGGCG 120

(2) INFORMATION FOR SEQ ID NO: 74:

(i) SEQUENCE CHARACTERISTICS:

30 (A) LENGTH: 128 base pairs

(B) TYPE: nucleic acid

35 (C) STRANDEDNESS: single

- 104 -

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 74:

5 GATCCGCCTG GCTGCACCAG GCCTCCGCCG CTCTCCACCA GCTGCACCTC GGAGTGGACA 60
CCTGTAGCTG TTGCTACCAA GAAGAGGATG ATACAGCTCC ATCCCATGGT GGCGGCGTCG 120
ACCCGC 128

10 (2) INFORMATION FOR SEQ ID NO: 75:

(i) SEQUENCE CHARACTERISTICS:

15 (A) LENGTH: 99 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

20 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 75:

25 GATGAACGGC CTGCAAGCCG AGGTGAGCGC CATCTACTAC TCGTTTCGCG ACCCATACTA 60
CTTCAGCGGC CACTACTTCG ACTTCTGGGG CCAGGGTAC 99

(2) INFORMATION FOR SEQ ID NO: 76:

(i) SEQUENCE CHARACTERISTICS:

30 (A) LENGTH: 99 base pairs

(B) TYPE: nucleic acid

35 (C) STRANDEDNESS: single

- 105 -

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 76:

5

CCTGGCCCCA GAAGTCGAAG TAGTGGCCGC TGAAGTAGTA TGGGTCGCGA ACGCAGTAGT 60
AGATGGCGCT CACCTCGGCT TGCAGGCCGT TCATCTGCA 99

(2) INFORMATION FOR SEQ ID NO: 77:

10

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 48 base pairs

15

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 77:

GATGAACAGC CTGCGCGCCG AGGACACCGC GGTATACTAC TGC GTTCG 48

25 (2) INFORMATION FOR SEQ ID NO: 78:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 53 base pairs

30

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

35

(D) TOPOLOGY: linear

- 106 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 78:

CGAACGCAGT AGTATACCGC GGTGTCCTCG GCGCGCAGGC TGTTTCATCT GCA 53

5

(2) INFORMATION FOR SEQ ID NO: 79:

(i) SEQUENCE CHARACTERISTICS:

10 (A) LENGTH: 435 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

15

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 79:

20 GTCGACGCCG CCACC ATG GGA TGG AGC TGT ATC ATC CTC TTC TTG GTA 48
Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val
-15 -10

25 GCA ACA GCT ACA GGT GTC CAC TCC GAG GTG CAG CTG GTG GAG AGC GGC 96
Ala Thr Ala Thr Gly Val His Ser Glu Val Gln Leu Val Glu Ser Gly
-5 1 5

30 GGA GGC CTG GTG CAG CCA GGC GGA TCC CTG CGC CTG AGC TGC GCC GCC 144
Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala
10 15 20

AGC GGC TTC AGC TTC CGC AGC TAC TGG ATG ACC TGG GTG CGC CAG GCC 192
Ser Gly Phe Ser Phe Arg Ser Tyr Trp Met Thr Trp Val Arg Gln Ala
25 30 35 40

35 CCG GGC AAG GGC CTG GAG TGG GTG GCC AGC ATC AGC ATC AGC GGC GAC 240
Pro Gly Lys Gly Leu Glu Trp Val Ala Ser Ile Ser Ile Ser Gly Asp
45 50 55

40 AAC ACC TAC TAC CCA GAC AGC GTG CGC GGC CGC TTC ACC ATC TCT AGA 288
Asn Thr Tyr Tyr Pro Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg
60 65 70

- 107 -

5 GAC GAC AGC AAG AGC ACC CTG TAC CTG CAG ATG AAC AGC CTG CGC GCC 336
 Asp Asp Ser Lys Ser Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala
 75 80 85
 GAG GAC ACC GCG GTA TAC TAC TGC GTT CGC GAC CCA TAC TAC TTC AGC 384
 Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg Asp Pro Tyr Tyr Phe Ser
 90 95 100
 10 GGC CAC TAC TTC GAC TTC TGG GGC CAG GGT ACC CTG GTG ACC GTG AGC 432
 Gly His Tyr Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser
 105 110 115 120
 15 AGC 435
 Ser

(2) INFORMATION FOR SEQ ID NO: 80:

(i) SEQUENCE CHARACTERISTICS:

20 (A) LENGTH: 232 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

25

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 80:

30 Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly
 -15 -10 -5
 Val His Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala
 1 5 10
 35 Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Ile
 15 20 25
 Tyr Lys Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys
 30 35 40 45
 40

-108-

Leu Leu Ile Tyr Asn Ala Lys Ser Leu Glu Thr Gly Val Pro Ser Arg
 50 55 60
 5 Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser
 65 70 75
 Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Tyr Ser
 80 85 90
 10 Gly Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val
 95 100 105
 Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys
 110 115 120 125
 15 Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg
 130 135 140
 20 Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn
 145 150 155
 Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser
 160 165 170
 25 Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys
 175 180 185
 Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr
 190 195 200 205
 30 Lys Ser Phe Asn Arg Gly Glu Cys
 210

(2) INFORMATION FOR SEQ ID NO: 81:

35

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 467 amino acids

40

(B) TYPE: amino acid

(D) TOPOLOGY: linear

-109-

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 81:

5 Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly
 -15 -10 -5
 10 Val His Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln
 1 5 10
 15 20 25
 15 Arg Ser Tyr Trp Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
 30 35 40 45
 50 55 60
 20 Glu Trp Val Ala Ser Ile Ser Ile Ser Gly Asp Asn Thr Tyr Tyr Pro
 65 70 75
 80 85 90
 25 Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
 95 100 105
 110 115 120 125
 30 Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys
 130 135 140
 145 150 155
 35 Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro
 160 165 170
 175 180 185
 40 Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr
 190 195 200 205
 45 Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn

- 110 -

Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser
 210 215 220

5 Lys Tyr Gly Pro Pro Cys Pro Ser Cys Pro Ala Pro Glu Phe Leu Gly
 225 230 235

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
 240 245 250

10 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln
 255 260 265

15 Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val
 270 275 280 285

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr
 290 295 300

20 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
 305 310 315

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile
 320 325 330

25 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
 335 340 345

30 Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser
 350 355 360 365

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
 370 375 380

35 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
 385 390 395

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val
 400 405 410

40 Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met
 415 420 425

45 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
 430 435 440 445

Leu Gly Lys

- 111 -

WHAT IS CLAIMED IS:

1. A polypeptide comprising a mature form of a variable region of a monoclonal antibody having an amino acid sequence shown in SEQ ID NO: 70 or SEQ ID NO: 79.
- 5 2. A humanized monoclonal antibody that specifically binds human IL-4 and comprises a mature form of a polypeptide of claim 1, or an antigenic fragment of such antibody.
- 10 3. A humanized monoclonal antibody of claim 2 characterized by mature light and heavy chains having amino acid sequences defined by SEQ ID NO: 80 and SEQ ID NO: 81, respectively, or an antigenic fragment of such antibody.
4. An antigenic fragment of either claim 2 or 3 that specifically binds human IL-4.
- 15 5. A nucleic acid encoding a polypeptide or antigenic fragment of any one of claims 1 to 4.
6. A recombinant vector comprising a nucleic acid of claim 5.
- 20 7. A host cell comprising a recombinant vector of claim 6.
8. A method for making a polypeptide, comprising culturing a host cell of claim 7 under conditions in which the nucleic acid is expressed.
- 25 9. An antibody against a monoclonal antibody or antigenic fragment of either claim 2 or 3.

- 112 -

10. A pharmaceutical composition comprising a
physiologically acceptable carrier and a monoclonal antibody
of either claim 2 or 3, an IL-4-binding fragment of such
antibody, or a complex comprising such antibody or binding
5 fragment bound to IL-4.

11. A method for the manufacture of a pharmaceutical
composition, comprising admixing a physiologically acceptable
carrier with a monoclonal antibody of claim 2, an IL-4-binding
fragment of such antibody, or a complex comprising such
10 antibody or binding fragment bound to IL-4.

	CDR1	CDR2	CDR3
LAY	<u>GFTFSASAMS</u>	WKYENGNDKHYADSVN	<u>DAGPYVSP</u> FFAH
25D2	S RSYW T	SISIS DNTY P	P-Y F GHY DF
h25D2H-1	S RSYW T	SISIS DNTY P	P-Y F GHY DF
h25D2H-2	S RSY	SISIS DNTY P	P-Y F GHY DF
h25D2H-3	SYW T	SISIS DNTY P	P-Y F GHY DF
h25D2H-4	SYW T	SISIS DNTY P	P-Y F GHY DF
h25D2H-5	S RSY	SISIS DNTY P	P-Y F GHY DF

CDR Loop
 — Overlap of CDR Loop and Kabat Region
 • Kabat Region

FIG. 1

2/3




FIG. 2




FIG. 3